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ABSTRACT
Calcium-dependent activator protein for secretion 1 (CAPS1) is involved in synaptic vesicle and
large dense core vesicle fusion by bridging vesicles and the plasma membrane prior to vesicle
fusion and cargo release. CAPS1 is subject to a post-transcriptional modification called RNA
editing. RNA editing recodes a single amino acid in the region of the protein that interacts with
the vesicle. This recoding event within CAPS1 has cellular consequences in neurons where
edited CAPS1 overexpression increases basal secretion from neural synaptic vesicles. Our goal
was to investigate how RNA editing within CAPS1 affects large dense core vesicle secretion in
an insulinoma cell type that secretes insulin. We modified CAPS1 editing frequency within
insulin-secreting cells, then measured non-stimulated and glucose stimulated secretion. We
found cells with increased non-edited CAPS1 had less basal secretion compared to normal
insulin-secreting cells, but edited CAPS1 did not affect secretion. Our study provides insight into
how even slight modifications of CAPS1 RNA editing frequency could have profound effects on
cellular secretion, which may suggest that CAPS1 editing is paramount to regulating cellular
processes like neurotransmission and glucose homeostasis.
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INTRODUCTION

Cells are complex machines, housing many subcellular processes that coordinate to make
the cell function. The human body relies on collaboration of its many cells by cell-to-cell
communication via the secretion of proteins, hormones, and other chemicals. Secretion is vital in
regulation of glucose levels, immunity, and neurotransmission and is an intricate process
controlled by a host of cellular factors. Disruption of secretion can cause disease, be a symptom
of disease, or may occur during the treatment of disease. Regardless of the origin, disruption in
this tightly controlled process can lead to drastic cellular and physiological consequences. For
example, type II diabetes inflicts about 10% of the United States population. Type II diabetes
develops when the body fails to release enough insulin or to respond to insulin signals that
control circulating glucose levels (reviewed in Koeck et al., 2015). The failure to control glucose
levels causes a wide array of complications, such as nerve damage, heart disease, increased risk
for developing other conditions, and more. The fight to cure diabetes is ongoing, but
understanding how insulin release occurs and the mechanisms of its regulation will help us better
understand the disease and potential treatments.

Secretion
Secretion is the process by which cellular products are released into an extracellular
space via fusion between a vesicle and plasma membrane. This event provides the means for cell
to cell communication and is fundamental to cell survival. Though all cells release an array of
contents that act as chemical signals on target cells, different cell types release different vesicle
types with different cargos. There are two major types of vesicles, small-clear vesicles (SVs) and
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large dense-core vesicles (LDCVs), which are utilized by a myriad of cell types. For example,
SVs release neurotransmitters and LDCVs release signaling peptides from neurons. Endocrine
cells typically utilize LDCVs to secrete hormones and other large peptides (Jahn and Südhof,
1999). The two types of vesicles also differ in origin, where SVs bud from early endosomes and
LDCVs originate from the trans-Golgi network (Kelly, 1993). Though there are stark differences
between the two, they follow the same basic fusion mechanics.
Fusion. Merging of vesicle and cell membrane lipid bilayers releases vesicle contents
into the extracellular space. There is some evidence that suggests two major modes of fusion can
occur: Full collapse fusion and “kiss-and-run” (Figure 1; reviewed in Rorsman and Renstrom,
2003). Full collapse fusion occurs when the vesicular membrane collapses completely and
merges fully with the plasma membrane, releasing all cargo. “Kiss-and-run” is the process where
a fusion pore forms, releasing a portion of cargo, then closes to re-form an independent vesicle
(Rutter and Hill, 2006).
The two modes of fusion both follow the same basic process for fusion pore formation.
Since each membrane is composed of acidic lipids, the membranes have an overall negative
charge, which should cause repulsion of the vesicular and plasma membranes. However, electron
microscope images reveal that medially the vesicular and cellular membranes are attracted to one
another, while laterally, the two membrane oppose one another. This results in a vesicular and
plasma membrane medial bilayer bending (Greengard, Valtorta, Czernik, and Benfenati, 1993).
Some evidence suggests positively charged amino acids in vesicle membrane-spanning proteins
may decrease the overall negative charge of the vesicle membrane, consequentially increasing
the electrostatic attraction between vesicle and plasma membranes (Williams, Vicôgne, Zaitseva,
McLaughlin, and Pessin, 2009). The medial bilayer bending eventually forms a stalk that allows
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lipid-mixing between the vesicle and plasma membrane, and then the fusion pore opens. During
full collapse fusion, the vesicle membrane lipids mix completely and the two bilayers merge.
During “kiss-and-run”, after a fusion pore forms, the membranes oppose one another medially,
pushing the vesicle internally from the membrane. This is a transient process, where vesicles
undergoing this type of fusion can repeatedly fuse with the membrane, release partial cargo, fully
release, or retract from the membrane for future fusion (Ceccarelli, Hurlbut, and Mauro, 1973).
Some literature suggests LDCVs in certain cell types prefer the kiss-and-run mode of
fusion. For example, cultured INS-1 (insulinoma) cells demonstrate “kiss-and-run” as the
primary release mechanism, where vesicles release partial contents approximately 90% of the
time and fully fuse with the membrane about 10% of the time (reviewed by Rorsman and
Renstrom, 2003). However, direct imaging indicates insulin-containing LDCVs in pancreatic
islet cells fuse completely with the membrane following stimulation (Ma et al., 2004). These
vesicles lingered at the membrane following stimulation, but did not undergo partial release, only
full fusion. SVs may also utilize both full fusion and “kiss-and-run”, though the degree is still in
question (Aravanis, Pyle, and Tsien, 2003).
Docking and priming. Vesicles undergo a series of events, termed “docking” and
“priming”, that prepare them for fusion. Typically, docking refers to anchoring of vesicles to the
plasma membrane. Priming refers to subsequent events that ready the vesicle for fusion, such as
protein-protein interactions or conformational changes in those proteins (Klenchin and Martin,
2000). Some evidence suggests these two events may be separate and distinct in neuroendocrine
cells (Nofal, Becherer, Hof, Matti, and Rettig, 2007). Distinction between to two processes are
supported by molecular manipulations that can alter the amount of readily releasable vesicles
(primed) without altering the number of docked vesicles (Gulyás-Kovács et al., 2007). Other
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sources characterize priming and docking by vesicle mobility at the membrane: Vesicles that
fused with the membrane within eight seconds were most likely primed vesicles and were
stationary at the fusion site prior to fusion. Vesicles that fused with the membrane after eight
seconds of stimulation traveled a greater distance along the membrane prior to fusion and were
most likely docked, but not primed (reviewed in Verhage and Sørensen, 2008).

Figure 1. Full collapse and “Kiss-and-Run” vesicle fusion. Vesicles that undergo full collapse
fusion will fully release cargo (purple) and the membrane will merge with the plasma membrane
(Top). Vesicles that undergo “Kiss-and-Run” mode of fusion form a fusion pore, release partial
contents, and retract from the membrane (Bottom). At times, this vesicle can transiently refuse
multiple times prior to full fusion.
Docking and priming proteins. Proteins are central to docking and priming. Soluble Nethylmaleimide-sensitive factor attachment receptors (SNAREs) are a family of proteins that
direct vesicles to any target membranes within the cell and can also recruit proteins for further
vesicular stabilization. Each SNARE protein contains a SNARE motif, a sequence approximately

4

65 amino acids long that forms a coiled-coil domain. SNAREs syntaxin, synaptobrevin (Vamp2), and synaptosomal nerve-associated protein 25 (SNAP-25), form a quartet of helices that
interact with calcium-sensor synaptotagmin to form the highly stable SNARE complex (Poirier
et al., 1998). Two of the four helices are motifs from SNAP-25 and the others are from syntaxin
and Vamp-2. Syntaxin, Vamp-2, and synaptotagmin each contain a C-terminal transmembrane
region (TMR) that embeds the protein into their respective lipid membranes. Synaptotagmin and
Vamp-2 are referred to as vesicular SNARES (v-SNARES) and are embedded in vesicular
membranes via their single coiled TMR. The target SNARE (t-SNARE) SNAP-25 and calcium
sensor synaptobrevin associate with the cellular membrane. Synaptobrevin contains a TMR
while SNAP-25 is a peripheral protein and only associates with the cytosolic surface of the
plasma membrane (reviewed in Goda, 1997).
Several members of the syntaxin family have been discovered, some which are involved in
fusion mechanics at the plasma membrane. These isoforms may play a role in targeting
specificity, as different isoforms are localized to different areas of the plasma membrane in
polarized cells, such as kidney cells (Low et al., 2007). Some syntaxins, like Syntaxin-1, is
further subdivided into isoforms 1A and 1B. The two isoforms are closely related and show
some functional redundancy in regulation of SV fusion of vesicles in the RRP (Mishima et al.,
2014). Both are heavily expressed in the nervous system (Bennett, Calakos, and Scheller, 1992)
though Syntaxin-1A is crucial to the docking process for LDCVs in cultured adrenal cells (PC12 cells) (S. Park et al., 2016). Syntaxin-3 has been found in specific vesicles involved in
stimulated release, but much unknown regarding its localization (Band and Kuismanen, 2005).
syntaxin contains a C-terminal SNARE domain which interacts directly with synapatobrevin and
SNAP-25 to form the center of the SNARE complex. The N-terminal region of syntaxin contains
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an Habc domain that is comprised of three alpha helices that binds to its own SNARE domain
when inactive. This state is commonly referred to as “closed” syntaxin and is generally incapable
of participating in the SNARE complex or vesicle docking. Conversion to “open” syntaxin is
required for vesicle fusion and depends on the presence of calcium and other proteins
(Borisovska, 2018). The open confirmation of syntaxin is characterized by its unbound N
terminal SNARE motif which makes it available for interactions with other SNARE proteins, an
essential function for vesicle fusion.
Prior to SNARE complex formation, the tSNARES and vSNARES are associated with
the plasma and vesicular membranes as cis-SNARE complexes. To ready for fusion, tSNARE
TMRs of proteins SNAP-25 and synaptotagmin homodimerize, causing the SNARE complex to
extend perpendicular from the cell membrane. v-SNARE TMRs also homodimerize leaving the
cytosolic N-termini free to eventually interact with the N-termini of the t-SNARE complexes
(reviewed in Ramakrishnan, Drescher, and Drescher, 2012).
As the vesicle approaches the membrane, the cis-SNARE complexes interact to form a
trans-SNARE complex, the conformation associated with vesicle docking. Docking is achieved
by rigid SNARE linker regions within the alpha helical bundle “zippering” the two associated
membranes together into proximity. This process requires precise timing and simultaneous
bending of all SNAREs. Premature folding of one SNARE TMR into the alpha helical bundle
could prevent the association of other TMRs (Lou and Shin, 2016). In the event where SNARE
domains are not anchored to the plasma membrane, the un-associated TMRs then relieve the
tension from their linker regions by kinking (Borisovska et al., 2012). This halts SNARE
zippering and prevents vesicle fusion (Han, Pluhackova, Bruns, and Böckmann, 2016). Precise
timing of TMR association is consistent with pore formation and full fusion. However, not all
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vesicle types have the same hurdles for full fusion. For example, it may be more difficult for
larger vesicles, like LDCVs, to fuse completely with the membrane, as the energetic barrier is
higher compared to small vesicles, such as SVs. These fusion energy barriers may be overcome
by increased numbers of SNARE complexes at fusion sites. SVs are associated with small and
point-like fusion sites that contains clusters of SNARE complexes. The point-like shape of the
fusion site allows rearrangement for SNARE complexes on either site of the fusion site and
likely contributes to lower energy barriers (Risselada and Mayer, 2020).
Some cell types use calcium-mediated exocytosis, where a rise in intracellular calcium is
required to overcome the energy barrier and trigger vesicle fusion. When cell calcium levels are
low, synaptotagmins exist embedded in the vesicular membrane via the TMR. Synaptotagmin
also contains two cytoplasmic C2 domains connected to the TMR by a flexible linker region.
Following an influx of calcium, the C2A region of synaptotagmin can bind two calcium ions
while the C2B domain can bind three. In this state, the C2A can bind to syntaxin while the basic
amino acid residues in the C2B domain interact with acidic phosphatidylinositol bisphosphate
(PIP2) in the lipid bilayer. Therefore, the rise in intracellular calcium triggered by various cellular
signaling pathways may trigger trans-SNARE complex or fusion pore formation (Chapman,
2008).
Munc18-1 is a protein in the Munc18/Sec1 family and is responsible for directing
vesicles to appropriate target areas on the cell surface for secretion. Predominantly in neurons,
Munc18-1 aids half-zippered SNARE bundles into full-zippered complexes (Shen et al., 2015).
In chromaffin cells, Munc18-1 has a high binding for Syntaxin-1 (Arunachalam et al., 2008).
Munc18-1 chaperones Syntaxin-1 delivery to the plasma membrane, which is consistent with the
findings that deletion of Munc18-1 greatly reduces Syntaxin-1 presence in the plasma membrane
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(Verhage et al., 2000). Munc18-1 also stabilizes Syntaxin-1 to the plasma membrane. It holds the
SNARE protein in a closed conformation where the Syntaxin Habc domain interacts with the
SNARE domain (Dulubova et al., 1999). Though Munc18-1 is primarily expressed in neural
tissue, functions of Munc18-1 are important for LDCV fusion in other tissue types. In PC-12
cells, the depletion of Munc18-1 reduces LDCV docking and abolishes cell secretion completely
(Voets et al., 2001). This evidence suggests that without Munc18-1, Syntaxin-1 is absent from
the fusion sites or is held in an open conformation, decreasing vesicle fusion. However, in
cultured kidney cells, absence of Munc18-1 halts secretion, but docked LDCV counts remained
unchanged (Verhage et. al, 2005). This evidence indicates Munc18-1 may play a larger role in
stabilization of Syntaxin-1, rather than SNARE complex assembly, and may help coordinate the
timing of SNARE zippering to promote full zippering of the SNARE complex (Risselada and
Mayer, 2020).
Munc18-1 contains a Munc homology domain (MHD), the region of the protein that
interacts with Syntaxin-1. Many other proteins contain MHDs. For example, Munc-13 contains
two MHDs near the C-terminus and alters the anchored, closed syntaxin into the open
conformation in the brain. The MHD closest to the N-terminus contains the syntaxin interacting
domain, though both MHDs are required to open syntaxin, freeing the SNARE protein for
SNARE complex formation and LDCV docking (Wang et al., 2017).
Calcium-dependent activator protein for secretion 1 (Caps1), another important protein
involved in exocytosis, also contains an MHD, which is required for LDCV fusion (W. Li et al.,
2011). Caps1 MHD domain, in conjunction with DUF1041 (domain of unknown function 1041),
make up the DAMH (DUF1041 and MHD1) domain (Figure 2) (Khodthong, 2011) which
interacts directly with syntaxin. DAMH spans from Caps1 amino acid residues 859 to 1036 and
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is comprised of four helical segments that run parallel and anti-parallel, connected by short,
flexible loops. Hydrophobic amino acids are retained on the inside of the domain while charged
residues face outward, promoting its ability for protein-interactions. (Zhou et al, 2019). Caps1
binding to syntaxin is accomplished by DAMH charged residues in outer helical regions
interacting directly with the syntaxin linker region. Evidence suggests binding of DAMH to
syntaxin is accomplished prior to vesicle docking (Khodthong, Kabachinski, James, and Martin,
2011). This could mean that Caps1 DAMH domain opens and stabilizes syntaxin prior to transSNARE formation (Zhou, 2019). This function is similar to Munc-13, the protein that binds to
syntaxin and transitions it from the closed to open state (Betz, Okamoto, Benseler, and Brose,
1997). However, Caps1 and Munc-13 have distinct roles in LDCV fusion. LDCV fusion in
CAPS1 knockout neurons and chromaffin cells could not be rescued by Munc-13 overexpression
(Liu et al., 2010).
Caps1 also interacts with exocytosis machinery and vesicles by other functional domains
that are required for exocytosis (van Keimpema, Kooistra, Toonen, and Verhage, 2017): the
coiled-coil domain (C2), LDCV binding domain (LDCVBD), and pleckstrin homology domain
(PHD) (Figure 2). The LDCVBD interacts directly with the vesicle (Figure 3). The PH domain
interacts with PIP2 in the plasma membrane and the C2 with phospholipids also in the target
membrane. The culmination of these interactions in conjunction with the DAMH domain suggest
that Caps1 tethers the vesicle at the plasma membrane and perhaps facilitates trans-SNARE
complex formation during fusion (reviewed in James and Martin, 2013).
The Caps1 C2 domain is comprised of residues 397-516 and forms a coiled-coil domain.
Coiled coils are the second most common domain, often present in proteins that self-associate or
heterodimerize with other proteins. The domain can have anywhere from two to five alpha
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helices, containing 7-11 amino acid repeats, which allow the helices to wind around one another
to form a supercoil (Lupas and Gruber, 2005). Typically, C2 domains are calcium-dependent,
however, the C2 domain in Caps1 does not appear to recognize calcium directly (Martin, 2014).
Instead, Caps1 C2 domain plays a role in homodimerization. In the cytoplasm and in vitro,
Caps1 appears to exist as a monomer. However, when at the plasma membrane and on vesicles,
Caps1 dimerizes via the C2 domain. When this C2 domain is deleted, Caps1 can no longer
facilitate LDCV fusion, indicating that dimerization is an important and required component for
vesicle docking and/or priming (Petrie et al., 2016).
The PH domain of Caps1 spans amino acid residues 523-624 and makes two
perpendicular anti-parallel beta sheets, connected by loops that can vary in length. The cytosolic
facing amino acids in the Caps1 PH domain are basic, and therefore are electrostatically attracted
to acidic elements. Though this domain can interact with acidic phospholipids, it appears to only
bind to the plasma membrane phospholipids and not vesicular phospholipids. The PH domain in
Caps1 is attracted to the PIP2 in the plasma membrane (Grishanin et al., 2002), which is modeled
to allow Caps1 to bring the LDCV close to the membrane for docking.
Caps1 bridges the plasma membrane and LDCV by interacting with PIP2 in the
membrane via PHD and with the outer surface of the vesicle membrane via the C-terminal
LDCVBD (Figure 4). This interaction is important in bringing the vesicle close to the membrane
for docking, but also plays a role in clustering dense core vesicles to the interior of the cells.
Caps1 mutants lacking a functional C2 domain led to more dispersed LDCVs. However, Caps1
with functional C2 domains capable of dimerizing leads to dense core vesicles that are more
tightly clustered together (Petrie et al., 2016).
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Figure 2. Secondary structure of calcium-dependent activator for secretion 1 and major
functional domains. Caps1 secondary structure in reference to N-terminus (N) and contains
calcium binding domain (C2, green), Plekstrin homology domain (PH, orange), Munc homology
domain (MHD, blue) and LDCV binding domain (LDCVBD, yellow). The locations of the
domain of unknown function (DUF1041) and syntaxin interacting domain (SID) are indicated
underneath the Munc homology domain.

Figure 3. Caps1 interactions with exocytosis machinery and plasma membrane. Caps1
major functional domains and their interactions are illustrated. Strength of interactions are
depicted by arrow weight. The C2 domain (green) has a weak interaction with the plasma
membrane. Plekstrin homology domain (orange) strongly interacts with acidic proteins in the
membrane, specificially PIP2, further stabilizing Caps1 at the membrane. Munc homology
domain (blue) interacts with synaptobrevin, SNAP-25, and strongly associates with syntaxin
(open conformation). The LDCV binding domain (yellow) strongly interacts with vesicle
membranes. Together, these interactions suggest that Caps1 helps tether the vesicle to the plasma
membrane during docking and/or priming, which helps to facilitate calcium mediate fusion of the
vesicle and release of vesicle contents (gold) into the extracellular space.
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Regulated Secretion
The fusion machinery and docking and priming proteins, such as Caps1, enable vesicle
fusion resulting from external stimulation. Outside stimuli (e.g. action potentials, ligand binding,
etc.) generate signals that lead to an increase in intracellular calcium, which triggers vesicular
fusion and release of cargo. The vesicle approaches the plasma membrane and docks
independent of the calcium level. When cytosolic calcium levels are low, Munc18-1 is bound to
syntaxin, preventing the transition to the open state and preventing the vesicle from fusing
completely with the membrane. When calcium binds to synaptotagmin, synaptotagmin alters
conformation, displacing Munc18-1, and inducing complete synaptotagmin binding with the
SNARE complex, fully zippering the two membranes together and allowing the membranes to
fuse (Tang et al., 2006). This calcium-mediated exocytosis is often referred to as stimulated or
evoked secretion.
Even in the absence of outside stimuli to trigger secretion, vesicles may still fuse with the
membrane, an event often described as “spontaneous release” (Kavalali, 2015). Spontaneous
release of SVs may still be dependent upon calcium, as calcium binding affinity of
synaptotagmin can vary to trigger calcium-dependent exocytotic events even with low levels of
intra-cellular calcium (Xu, Pang, Shin, and Südhof, 2009). These events are asynchronous,
unlike evoked release that occurs in a manner timed with an action potential or extracellular
trigger. There may be a specific subpopulation of vesicles capable of spontaneous fusion marked
by proteins similar to synaptotagmin, but have high-affinity calcium binding properties (Chung
and Raingo, 2013).
LDCVs releasing neuropeptides from neuroendocrine cells have been reported to undergo
slow spontaneous release. Vesicle fusion resembled “kiss-and-run”, where cargo was released
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slowly during spontaneous fusion due to narrow fusion pore formation and slow peptide
diffusion rates. Upon stimulation, the same vesicles that were undergoing slow spontaneous
fusion can be triggered to fuse completely after vesicle pores continued to open and narrow
repeatedly before finally fusing completely (Vardjan, Stenovec, Jorgačevski, Kreft, and Zorec,
2007).
Vesicles are arranged into three functional pools; the readily releasable pool, recycling
pool, and the reserve pool (Rizzoli and Betz, 2005). In mouse islet cells, approximately 1-5% of
all vesicles are held in the readily releasable pool (RRP), the pool of vesicles docked and primed
at the cell membrane, awaiting an outside stimulus that will trigger rapid release (Barg, Eliasson,
Renström, and Rorsman, 2002) (Figure 4). Most of the remaining LDCVs belong to the reserve
pool, which have yet to undergo docking and priming. In pancreatic beta cells, the RRP is 0.21% of total insulin granules (P. Rorsman and Renstrom, 2003). In neurons, approximately 1020% of synaptic vesicles make up the recycling pool (RP), where vesicles are mobile and
scattered in the synaptic terminals and participate in fusion and vesicle recycling with moderate
stimulation. The remaining vesicles are fixed, or tethered, in a reserve pool away from the
periphery of the cell and require strong stimulation to migrate to the cell surface and release
(Rizzoli and Betz, 2005).
Vesicles are also organized temporally, and their release helps define phases of fast, slow,
and sustained release (Braun, Ramracheya, Johnson, and Rorsman, 2009). During fast release,
RRP vesicles fuse with the plasma membrane within milliseconds after an increase in cytosolic
calcium (reviewed in Komatsu, Takei, Ishii, and Sato, 2013a). These vesicles are docked and
primed at the plasma membrane surface at the time of stimulation, contributing to their timely
release. A slower sustained release occurs when groups of unprimed vesicles that are released
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slowly and consistently throughout several seconds of continued stimulation (reviewed in
Stevens et al., 2011), likely because the RRP has been depleted. The vesicles released in this
sustained phase are thought to be recruited from the reserve and recycling pools and require time
to complete docking and become fusion competent (Rorsman and Renstrom, 2003).
While vesicle distance from the plasma membrane is often used to diagnose docking, this
does not always correlate to release time. Only a small subset of vesicles at the membrane
release immediately upon stimulation. Some estimates show that LDCVs release about 30% of
morphologically docked insulin granules rapidly upon stimulation (P. Rorsman and Renstrom,
2003). This initial phase of release are vesicles that are primed, while the later phases correlated
with unprimed insulin granules (Ohara-Imaizumi et al., 2007).

Figure 4. Conversion of reserve pool vesicles into docked, primed, and readily releasable
vesicles. When a large stimulus occurs, reverse pools migrate to the plasma membrane to replace
the readily releasable pool. Synaptotagmin (green) and synaptobrevin (purple) interact with
syntaxin (red) and SNAP-25 (blue) during docking. Exocytosis machinery and additional
proteins such as Caps1 interact, the SNARE complex fully zippers, and the vesicle is immobile
at the membrane (primed). These primed vesicles are a part of the readily releasable pool (RRP).
Upon a stimulus that raises the intracellular calcium level, the docked and primed vesicles of the
RRP rapidly fuse and release cargo into the extracellular space.

14

Glucose-stimulated exocytosis. Pancreatic beta cells undergo regulated secretion in
response to increased blood glucose levels. This release of insulin stimulates glucose uptake
from the blood into the cell to use as energy. These pancreatic beta cells are one of three types of
cells located in pancreatic islets and make up approximately 75% of islets. Alpha cells make up
20% of islets and secrete glucagon to release stored glucose when circulating glucose levels are
low (reviewed in Chen, Cohrs, Stertmann, Bozsak, and Speier, 2017). The other 5% of
pancreatic islet cells are delta cells, which counter the activity of neighboring alpha and beta
cells. Delta cells secrete somatostatin to inhibit both glucagon and insulin secretion when glucose
levels approach homeostasis (Patrik Rorsman and Huising, 2018).
Glucose stimulate insulin secretion (GSIS) from pancreatic beta cells is a highly
regulated process is a prominent example of hormone release from LDCVs. Insulin release is
biphasic, where the first phase of secretion releases vesicles held in the RRP while the release of
vesicles from the RP pertain to the sustained second phase of release. Biphasic release occurs via
two distinct pathways: the KATP channel-dependent and KATP channel-independent pathways
(Komatsu, Takei, Ishii, and Sato, 2013). In the former, glucose traverses the beta cell plasma
membrane via GLUT2 receptors in rodents and GLUT1 and 2 in humans and is processed
through glycolysis and the citric acid cycle (TCA). By-products adenosine triphosphate (ATP)
and nicotinamide adenine dinucleotide phosphate (NADPH) are key metabolic coupling factors
in the GSIS KATP channel-dependent signaling pathway. Through glycolysis, NADP+ accepts an
electron, becomes NADH, and shuttles the electron into the mitochondrial electron transport
chain. This creates a hydrogen gradient used to power ATP synthetase, which converts adenosine
diphosphate (ADP) into ATP, increasing the ratio between cellular ATP and ADP (reviewed in
Rorsman and Renstrom, 2003). Increasing ATP closes KATP channels and consequentially
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depolarizes the cell (Cook and Hales, 1984). Depolarization opens calcium ion channels
proximal to sites of exocytosis, which allows calcium binding to SNARE calcium sensor
machinery, and triggers the fusion of insulin granules in the RRP (Wollheim and Sharp, 1981;
Satin, 2000).
The KATP channel-independent pathway of insulin secretion is less understood, and is
responsible for the second phase of insulin release (Taguchi, 1995). Though there are many
hypotheses that aim to explain the second phase of release, it is heavily supported that
replenishing TCA intermediates drives the second phase of insulin release forward. One specific
intermediate, malonyl-CoA, has a directly proportional relationship with insulin secretion, such
that an increase in malonyl-CoA increases insulin release under GSIS. Malonyl-CoA functions
by preventing fatty acid (FA) binding to carnitine palmitoyl-transferase and inhibiting transport
into the mitochondria where FA oxidation occurs. This oxidation occurs via LC-CoA, and
without FA in the mitochondrion, LC-CoA accumulates in the cytosol where it can be esterified
into diacylglycerol (DAG) and PIP2 (reviewed in Komatsu et al., 2013). DAG is also produced
following glucose-induced calcium influx. Calcium activates phospholipase C, which hydrolyzes
PIP2 into inositol triphosphate and DAG. DAG is also involved in the docking and priming
process. DAG binds to Munc-13, inducing a conformational shift, and tightens the SNARE
complex. This induces vesicular and plasma membrane fusion (Xu et al., 2017).
DAG also plays indirect roles in regulating exocytosis via PKC activation. DAG moves through
the plasma membrane and activates PKC. For example, in chromaffin cells, SNAP-25
phosphorylation by PKC causes consequential rapid exocytosis and vesicle recruitment to the
membrane (Nagy et al., 2002). Caps1 is phosphorylated by PKC in neural cells (Nishizakis,
Walent, Kowalchyk, and Martins, 1992) though this process does not seem to have clear effects
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on Caps1 activity (Nojiri et al., 2009). Though PKC regulates proteins, it may play a bigger role
in vesicle rearrangement and migration by interacting directly with the cellular cytoskeleton.
PKC, the Cytoskeleton, and Vesicle Mobility. The cytoskeleton plays an important role in
vesicular mobility, both restraining vesicles and guiding them to their targeted sites for
exocytosis. Electron micrographs of chromaffin cells show a large web of actin filaments
interacting with outer membrane of vesicles (Nakata and Hirokawa, 1992). Filaments are
arranged asymmetrically within the cell where inner regions of the cytoplasm lack filamentous
bundles, while regions closer to the plasma membrane contain filamentous bundles between
LDCVs. These bundles may explain the compartmentalization of vesicles to specific pools in the
cell and offer a method for controlling release of secretagogues (Giner et al., 2011).
The cytoskeleton that divides vesicles into pools is not static as previously thought
(Aunis and Bader, 1988), and is PKC-induced in many cells including pancreatic beta,
chromaffin, and neural cells (Y. S. Park et al., 2006a; Vaughan, Walker, and Peers, 1998).
Increased PKC activation is directly proportional to both first and second phases of insulin
release (Vitale, Seward, and Trifaro, 1995). It is interpreted that sustained release of insulin
occurs through the recruitment of vesicles from the reserve pool to the RRP by the PKC-directed
release of myristoylated alanine-rich C-kinase substrate (MARCKS) from the plasma membrane.
The translocation of PKC to the membrane releases MARCKS which correlates with filamentous
actin disassembly (Y. S. Park et al., 2006b) and rearrangement (D. Giner et al., 2011). Actin
disassembly allows vesicles in the RP to replenish the ones released from the RRP following the
same calcium influx (Rodriguez Del Castillo et al., 1990; Giner et al., 2011; Parsons, Coorssen,
Horstmann, and Almers, 1995).
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Glucose-stimulated secretion and syntaxins. SNAREs are likely the key to the first,
rapid phase of insulin release during GSIS. Pancreatic beta-cells rely predominantly on Syntaxin1A and Syntaxin-3 for insulin release. In mice lacking Syntaxin-1A, pancreatic beta cells did not
undergo first phase insulin release. However, the second sustained phase was preserved
(Henquin, 2000). This suggests the SNARE activity and machinery are different for each insulin
release phase. SNAP-25 and Syntaxin-1A expression is decreased in islets of type II diabetic
patients (Ostenson et al., 2006). Furthermore, monitoring fluorescently tagged Syntaxin-1A and
insulin in pancreatic cells during glucose stimulation assays shows that LDCVs and Syntaxin-1A
interact during the first phase of release, but do not during the second release phase (OharaImaizumi et al., 2007). Conversely, Syntaxin-3 is most frequently localized to vesicles associated
with the second phase of insulin release. Syntaxin-3 ablation results in the disruption of the
second phase. This suggests that different syntaxin isoforms are involved with different modes of
release, where Syntaxin-1 frequently regulates release from the RRP and Syntaxin-3 regulates
vesicle release from the RP (Zhu et al., 2013).

CAPS1 and RNA Editing
As discussed earlier, Caps1 is a key factor in regulated secretion via its major functional
domains: C2, PH, DAMH, and LDCVBD. Caps1 participates in docking and/or priming by
bridging the plasma membrane and vesicle, promoting fusion (Figures 3 and 4). Caps1 is a key
component of secretion and its disruption has severe consequences. Caps1 deficiency results in
decreased SV release from mouse neurons (Sadakata et al., 2013). More extremely, Caps1 is
essential to life, as ablation in mice is embryonically lethal (Wang et al., 2000). Caps1 is
essential due to its role in secretion, but it also plays a role in disease progression. Decreased
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Caps1 expression in liver tumor cells results in tumor progression and poor patient prognosis
while overexpression in liver tumor cells increases activation of cellular apoptotic pathways
which decreases tumorigenesis (Xue et al., 2016). Similarly, overexpressing Caps1 negatively
regulates tumorigenesis in cholangiocarcinomas (Weng et al., 2019). Thus, Caps1 may act as a
tumor suppressor in certain cell lines, though the mechanisms behind this involvement are
unclear.
The transcript encoding Caps1 is modified post-transcriptionally through a process
termed Adenosine-to-Inosine (A-to-I) RNA editing ( Li et al., 2009). A-to-I editing alters a
genetically encoded glutamic acid (GAG) into a glycine (GGG) at amino acid 1250 in humans
and 1252 in mice (Miyake et al., 2016).
RNA editing. RNA editing is a post-transcriptional modification where nucleotides
within a transcript are inserted, deleted, modified, or substituted. Post-transcriptional base
substitutions occur when an individual nucleotide is altered to generate a different nucleotide.
Two specific types of base substitutions due to RNA editing are cytidine-to-uracil (C-to-U) and
A-to-I editing. A-to-I editing modifies adenosine (A) into inosine (I) by deamination, which
replaces the amine group on the adenosine base with a double-bonded oxygen. Inosine and
guanosine are structurally similar, so if editing occurs within a coding region, ribosomal
machinery recognizes I as G. If the editing event occurs with a codon, it has the potential to alter
the amino acid sequence of the encoded protein. For example, modification of a genomically
encoded GAG to GIG causes preferential pairing with tRNA anticodon CCC during translation
(Figure 5), which results in the addition of glycine, instead of glutamate, within the LDCVBD of
the growing Caps1 polypeptide ( Li et al., 2009).
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RNA-editing can provide a means for adaptability and diversity (Maas, Melcher, and
Seeburg, 1997; Rueter and Emeson, 1998). Diversity not only pertains to the variability between
organisms, but also the variability within a single organism. RNA-editing is rarely an all-ornothing event, allowing multiple isoforms of a non-coding RNA or protein to exist
simultaneously. A-to-I RNA editing within coding regions is relatively rare (Xu and Zhang,
2014), and only 3% of human transcripts contain recoding RNA editing sites where editing will
alter the coding potential of the mRNA (Liscovitch-Brauer et al., 2017). These recoding events
are highly conserved in mammals and each event seems to result is significant alteration of
protein function (Pinto, Cohen, and Levanon, 2014).
The recoding of a protein by RNA editing can result in dramatic physiological
consequences. For instance, in apolipoprotein B mRNA, a CAA codon that is deaminated to the
UAA stop codon. This reaction results in truncated ApoB48 protein variant, while the unedited
mRNA is translated into the full ApoB100 (Teng, Verp, Salomon, and Davidson, 1990). The
truncated protein operates quite differently than the full ApoB100. The unedited ApoB transcript
results in the major protein constituent of very low-density lipoproteins in the liver and aids in
cholesterol transport, while ApoB48 is produced in the small intestine, aiding in fat absorption
and secretion of chylomicrons (Teng et al., 1990). These distinct proteins arise from the same
gene, further supporting the concept that not all proteins are encoded directly by the genome.
Another example how RNA editing can have physiological consequences lies with the
GluA2 subunit within AMPA receptors. RNA editing occurs within the transcript, altering
genomically encoded glutamine to arginine within the narrowest part of the ion channel
(reviewed in Rosenthal, 2015). Glutamine at this point in the channel causes the receptor to be
impermeable to calcium, which is detrimental to neural activity. However, the alteration to
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arginine allows calcium permeability. This editing event from glutamine to arginine occurs in
near 100% of the transcripts and is the most prevalent RNA editing event known. Furthermore,
reduced RNA editing of GluA2 is lethal to neurons and potentially to the organism (reviewed in
Rosenthal, 2015).
A majority of RNA editing occurs in noncoding regions of pre-mRNAs, such as 5’ and 3’
untranslated regions (UTRs) and introns, or within non-coding RNAs (Peng et al., 2012).
Approximately 90% of the known editing sites within noncoding regions occur in Alu repeats.
Alu repeats are SINEs (short interspersed elements) that are frequently located near or within
gene-rich regions and can affect gene regulation (Krebs et al., 2018). If Alu repeats are located
within transcribed regions, and occur back-to-back and inversely, the resulting RNA can form a
hairpin or duplex. Since the enzymes that catalyze RNA editing target regions of double stranded
RNA, the inverted Alu repeats are a target for A-to-I editing. Multiple A-to-I modifications can
occur in this transcript, even though this region is not designed to be specifically targeted for Ato-I editing. This non-specific editing of long regions of dsRNA is known as hyper-editing.
Hyper-editing occurs within CAT2 3’UTR due to an Alu repeats within the last exon. Inverted
Alu repeats within the 3’UTR form a duplex and is hyper-edited, where up to 50% of A
nucleotides are altered (Prasanth et al., 2005). CAT2 is only one of the millions of examples how
Alu repeats influence RNA editing. In fact, Alu repeats are widespread in the in the human
transcriptome and are responsible for the majority of RNA editing within the human
transcriptome. This hyper-editing differs from regulated site-selective editing, but both require a
Adenosine Deaminases Acting on RNA (ADAR) for catalysis (reviewed in Rosenthal, 2015).
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Figure 5. A-to-I RNA editing during translation. Following A-to-I editing events
where adenosine is modified into inosine, ribosomes fail to recognize structural differences
between guanosine and inosine. Consequentially, ribosomes pair inosine with a cytosine
nucleotide during translation. While the genomically encoded CAG codon normally codes for a
Glutamic acid (Q), the edited codon (CIG) would encode an arginine (R) in the nascent
polypeptide chain.
Adenosine deaminases acting on RNA. ADARs are the enzymes that catalyze A-to-I
RNA editing. ADAR proteins are not sequence specific, but instead are structure specific,
recognizing double stranded RNA (dsRNA) through their dsRNA-binding domains (dsRBD).
When ADARs hyper-edit, their dsRNA substrates are typically long without bulges or loops,
whereas selective editing events typically occur within imperfect dsRNA substrates, containing
loops and bulges (Lehmann and Bass, 1999). The differences in ADAR editing activity between
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these two types of substrates could provide insight into how substrate structure regulates ADAR
binding and editing.
Three different ADAR genes exist in vertebrates. ADAR1, ADAR2 and ADAR3 are
similar in sequence and have dsRNA binding activity (Chen et al., 2000). Only ADAR1 and
ADAR2 have catalytic capabilities and homodimerize (Gerber and Keller, 1999; Kim, Wang,
Sanford, Zeng, and Nishikura, 1994; C. X. Chen et al., 2000; Cho et al., 2003). Though ADAR1
and ADAR2 have similar structures and capabilities, the roles are not redundant as ADAR1 does
not rescue ADAR2 editing deficiency (Chalk, Taylor, Heraud-Farlow, and Walkley, 2019).
ADAR1 and ADAR2 edit distinct targets, but also coordinately regulate a subset of RNA editing
sites (Costa Cruz et al., 2020).
ADAR1 is derived from the ADAR gene in chromosome 1, spanning over 46,000 bp and
encoding 17 different exons. Within the ADAR gene are four different promoter regions. Three of
these regions are constitutively active while one promoter region is interferon inducible. The
constitutive promoter will produce a 110 kilodalton protein (ADAR1p110) and interferon will
induce production of a longer 150kD version (ADAR1p150) (reviewed in Nishikura, 2010).
ADAR1p150, ADAR1p110 and ADAR2 all contain a catalytic deaminase domain,
double stranded RNA binding domains, and a nuclear localization signal (NLS). The NLS allows
ADAR to reside in the nucleus and edit transcripts co-transcriptionally and/or immediately after
transcription (Stefan Maas and Gommans, 2009; Rodriguez, Menet, and Rosbash, 2012).
ADAR1p150 also contains a nuclear export signal that allows it to shuttle out of the nucleus to
potentially edit transcripts in the cytoplasm. ADAR1p150 contains two Z DNA binding domains
at its N-terminus, while p110 contains only one (dsRBMs; Figure 6).
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Figure 6. ADAR1 isoforms. ADAR1p150 contains and extended N-terminus with one more Z
DNA binding domain (Z) and a Nuclear Export Signal (NES), compared to ADAR1p110. Both
contain dsRNA binding domains (dsRBMs), nuclear localization signal (NLS) and a deaminase
domain (adapted from Hood et al., 2014).
Physiological consequences of ADAR and RNA editing. ADAR proteins are required
for survival. Mice without ADAR2 experience seizures and die shortly after birth. This is
primarily due to GluA2 editing, which is required to be maintained at near 100% for
maintenance of calcium permeability. Mice that contain a synthetically edited GluA2 gene
(genomic A to G substitution) but lack ADAR1, survive (Higuchi et al., 2000). Lack of ADAR1
leads to embryonic death due to widespread apoptosis (Herbert, Wagner, and Nickerson, 2002).
This is likely because ADAR1 acts as an important interferon suppressor and protects organisms
from inflammation, cancer, and autoimmune disorders (reviewed in Gallo and Locatelli, 2012).
Evidence indicates ADAR RNA editing capabilities have a direct effect on cellular
function. Deficits in ADAR RNA editing but not in dsRNA binding function lead to locomotion
defects in Drosophila (Deng et al., 2020). Additionally, ADAR1 has been gaining attention for
its involvement in innate immune functions. Gene expression assays in Drosophila with
catalytically inactive ADAR demonstrate increased expression of proteins involved in innate
immunity (Deng et al., 2020). ADAR2 editing capabilities play a pivotal role in regulated
secretion. Disabling ADAR2 editing capabilities impairs GSIS within rat INS-1 cells and
secretion is rescued when wild-type ADAR2 is reintroduced. Deficiency in secretion could be
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explained by decreased expression of Munc18-1 and synaptotagmin when ADAR2 is not
present. This indicates ADAR2 RNA editing function plays an important role in GSIS (L. Yang
et al., 2010).
RNA editing, CAPS1 and secretion. The CAPS1 transcript is edited with an average of
about 20% frequency in mouse and human tissue. However, adrenal glands experience an
increased editing rate, near 80%, while 40% of CAPS1 transcripts are edited in pancreatic tissue
(Miyake et al., 2016). The wide-spread and conserved RNA editing of CAPS1 suggests that its
editing is important to physiology of the organism.
RNA editing of CAPS1 transcript has significant effects on regulated secretion. Mice
expressing only the edited transcripts demonstrated increased LDCV exocytosis in mice. In
addition, these mice are leaner compared to the control mice due to increased metabolic rates.
The increased metabolism in these mice is thought to be due primarily to the increased secretion
of dopamine from LDCV (Miyake et al., 2016). In cultured neurons, increasing the ratio between
Caps1 edited and Caps1 non-edited isoforms decreased spontaneous release from SVs (Ulbricht
et al., 2017). Additionally, edited Caps1 reorganized the neural RP. Edited Caps1 decreased RP
volume and increased the sphericity of the RP, suggesting edited Caps1 tightly clustered
vesicles.
Caps1 interacts with different isoforms of exocytosis machinery. For example, Caps1
associates with Syntaxin-1A linker region peptides but does not bind to Syntaxin-3 linker region
peptides (Daily, Boswell, James, and Martin, 2010). Additionally, evidence suggests edited
Caps1 strongly interacts with Syntaxin-1 linker region while non-edited Caps1 binds less
effectively (Miyake et al., 2016). These interactions between edited Caps1 and Syntaxin-1A may
explain how edited Caps1 increases SV secretion from neurons. However, this is only a piece of
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the bigger picture. Further information is needed to understand Caps1 mechanics and how
editing of the transcript affects LDCV secretion from endocrine cells.

Investigating the Role of CAPS1 RNA Editing on Secretion
Modification to RNA-editing of CAPS1 affects secretion from LDCV and SVs. A minor
decrease in editing frequency of CAPS1 mRNA (5 %) increases spontaneous release of SVs
(Ulbricht et al., 2017). Expression of only edited Caps1 in mice have increased secretion from
LDCVs in isolated chromaffin cells (Miyake et al., 2016) It is not clear if CAPS1 editing affects
on LDCV release are universal to all cell types, or are unique to chromaffin types of cells. It is
also unclear if CAPS1 editing effects on spontaneous release occur outside of neurons or on
LDCVs, as non-stimulated events are largely un-reported. Our goal is to determine the role of
CAPS1 mRNA editing on regulation of LDCV secretion in insulinoma cells. To address this
goal, we will alter RNA-editing frequency of CAPS1 in INS-1 cells. Previous mechanisms for
modulating the presence of edited CAPS1 include overexpression of edited CAPS1 cDNA
(Ulbricht et al., 2017) and altering the genomic A to a G within the CAPS1 E/G site (Miyake et
al, 2016). We will use several methods, including CRISPR/Cas13 technologies, in attempts to
manipulate the editing level of CAPS1 RNA.
We will measure secretion from INS-1 cells by quantifying secretagogues within cell
culture media. Basal secretion of secretagogues during normal, non-stimulating conditions will
provide insight on how CAPS1 editing affects spontaneous LDCV fusion. I expect increasing
editing frequency of CAPS1 within cultured INS-1cells will decrease spontaneous release of
LDCVs, detected by fewer secretagogues in the INS-1 media under basal (low glucose)
conditions. We will use high glucose conditions to induce GSIS and test how variations in
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CAPS1 editing levels affect efficiency of LDCV fusion under stimulating conditions. GSIS is
expected to increase in the presence of edited Caps1 if calcium-dependent secretion is modulated
in INS-1 cells similarly to PC-12 and chromaffin cells.
Manipulating CAPS1 editing. The INS-1 cell line is a pancreatic beta insulinoma
derivative from Rattus norvegicus. The INS-1 cells express Caps1, which is likely important for
robust GSIS from these cells. The CAPS1 RNA in these cells is almost entirely nonedited. We
will use three potential methods to increase editing of CAPS1. In the first, we will overexpress
ADAR1. It is possible that increasing the enzyme responsible for RNA editing within CAPS1
mRNA will increase editing frequency. However, ADAR1 and 2 expression levels do not
directly correlate with the extent of editing frequency in mouse neurons (Jacobs, Fogg, Emeson,
and Stanwood, 2009), therefore, it is possible that increasing ADAR expression in INS-1cells
may not increase editing within CAPS1 mRNA. Second, we will attempt to increase editing of
CAPS1 using a relatively new tool, RNA Editing for Programmable A to I Replacement, or
REPAIR. REPAIR uses a catalytically inactive Cas13 fused with a hyperactive ADAR
deaminase domain. A small RNA complementary to the CAPS1 E/G editing site will guide the
Cas13-ADAR fusion to the RNA, where the Cas13-ADAR will edit the RNA (Qu et al., 2019).
The chances of this method being successful are limited by the targeting efficiency of the guide
RNA (gRNA). Therefore, if the REPAIR is unsuccessful, we will attempt to knockdown the
endogenous CAPS1 RNA using wild-type Cas13b, and replace expression of CAPS1 from
plasmids expressing either edited (G) or nonedited (E) CAPS1. Finally, if our attempts to
knockdown CAPS1 are unsuccessful, we will increase the proportion of edited to non-edited
Caps1 variants in INS-1 cultures by expressing edited CAPS1 cDNA from a plasmid. While this
final method has its limitations and may limit the resolution, it may be considered more similar
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to disease or physiological conditions where we expect editing to more subtly change, rather than
to entirely disrupt endogenous editing ratios.
Measuring LDCV secretion from INS-1 cells. After altering the levels of CAPS1
editing within INS-1 cells, we will utilize this model to study secretion. We will administer
cDNA encoding fluorescently tagged secretagogues and measure fluorescence in cell media
during both non-stimulated and stimulated conditions. Secretagogues in the media represent
LDCV exocytosis, where greater fluorescence correlates with more LDCV fusion events.
Secretagogue fluorescence will first be measured following incubation under low glucose, nonstimulating conditions. Afterward, cells will be incubated in high glucose cell culture media to
induce GSIS and secretagogue fluorescence will be measured again. I expect cells in which
edited Caps1 is increased will show lower fluorescence in the media following basal conditions
compared to cells with only non-edited Caps1. Less fluorescence would indicate fewer LDCV
fusion events during basal conditions, meaning the presence of edited CAPS1 decreases
spontaneous LDCV fusion and editing is more controlled. I expect INS-1 cells to secrete more of
the fluorescent marker in the presence of high glucose compared to baseline if GSIS is working
properly. Additionally, I expect cells greater levels of edited Caps1 to have higher levels of GSIS
than those with only non-edited Caps1. Greater secretion of the fluorescent marker would
indicate more LDCV fusion events during stimulation, an observation consistent with previous
findings in chromaffin cells (Miyake et al., 2016).
Impact of study. Successful modulation of edited Caps1 in INS-1cells and measurement
of LDCV exocytosis will provide insight on how Caps1 affects LDCV secretion. If our
hypothesis is correct and increased edited Caps1 increases LDCV exocytosis following
stimulation and decreases spontaneous LDCV release in non-stimulating conditions, it is possible
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Caps1 could be a therapeutic target to rescue secretion of other secretagogues, such as insulin.
Since INS-1 cells release insulin form LDCVs in response to high glucose levels, edited Caps1
may also improve stimulated release of insulin similarly to the fluorescent secretagogues used in
this experiment. Improving the release of insulin from pancreatic -cells may have therapeutic
potential for type II diabetes, a disease that has diminished insulin secretion in response to high
blood glucose levels.
This study will also provide insight into the therapeutic potential for manipulation of
RNA editing in vivo. If slight modulations in CAPS1 editing, rather than complete obliteration or
replacement, are capable of altering secretion, then perhaps slight perturbations of editing are
responsible for phenotypes associated with disease. Furthermore, methods that can alter editing
of CAPS1, even slightly, could potentially improve these phenotypes. Though our results may
give insight on edited Caps1 and secretion, our study is confined within the scope of cultured
INS-1cells. While we expect these results to be applicable across systems, utilization of these
methods with other cell lines would broaden the scope and provide further insight on Caps1 and
its role in cell secretion.
Finally, it is interesting that the biochemical alteration of a single amino acid in a large
protein (~150 KDa) would affect secretion efficiency, even when only a fraction of the proteins
contain the alteration. While RNA editing substitutes a non-polar glycine for the genomically
encoded glutamic acid (ionic), the biochemical characteristics that facilitate changes in Caps1
function are not yet known. This work will provide insight into the qualities and conditions that
RNA editing and Caps1 isoforms play in important cellular process.
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MATERIALS AND METHODS
Plasmid DNA Isolation and Purification
To meet our goal and understand how RNA editing frequency within CAPS1 affects
LDCV secretion from INS-1 cells, we first needed to modify RNA editing frequency. We
attempted to modify frequency by REPAIR, that uses CRISPR RNA complementary to CAPS1
RNA, and catalytically inactive Cas13 attached to the RNA editing ADAR domain (Cas13ddADAR). The crRNA brings Cas13 close to CAPS1 and the targeted adenosine nucleotide for
RNA editing. Since ddADAR is close to the editing site, theoretically, it should modify
adenosine to inosine. To accomplish REPAIR, CRISPR-Cas13-ddADAR (Addgene 103849;
pRU 86), non-targeting crRNA (Addgene 103868; pRU 88), crRNA backbone (Addgene
103854; pRU 87) and CRISPR-Cas13 (Addgene 103862; pRU 91) plasmids were obtained from
Addgene (Cox et al., 2017), and streaked onto Luria Broth agar plates containing 100 µg/mL
ampicillin for selective pressure, and incubated at 37℃ overnight. Single colonies were isolated
and inoculated in 10 mL of Luria Broth and 100 µg/mL ampicillin and incubated at 37℃
overnight in Benchmark Incu-shaker. These inoculations were then transferred the following day
to 150 mL of Luria Broth and ampicillin. Plasmids were isolated via the Wizard Plus SV
Midiprep kit and supplied protocol (Promega A1460) and stored at -20 °C. Cas13-ddADAR
functions in conjunction with a gRNA that is unique and complementary to the target. Therefore,
the gene encoding gRNA needed to be made and inserted into the crRNA backbone plasmid.

Cloning Guide RNA into crRNA Backbone
The crRNA plasmid first needed to be digested into a linear strand for gRNA gene
insertion. The crRNA backbone was subject to a 10 µL restriction digest comprised of 2 µg of
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purified crRNA backbone plasmid, 1 µL of FastDigest BpiI (ThermoFisher Scientific FD1014),
and NEB buffer 3.1. The reaction was incubated in a water bath for 10 minutes at 37 ℃. To
prevent the linear crRNA backbone from circularizing, the vector was dephosphorylated with 1
µL of Antarctic phosphatase (NEB M0289S) and incubated at 37 ℃ for 30 minutes. DNA was
purified using the Promega Wizard SV Gel and PCR Clean-Up System and supplied protocol
(A9280) and stored at -20 °C.
The crRNA in the backbone plasmid lacks the targeting RNA complementary to the
CAPS1 transcript. Thus, oligonucleotides (Table 1) were used to insert a crRNA gene cassette
into the vector. To prepare for cloning, the oligonucleotides were first phosphorylated at the 5’
end in 40 µL reaction mixtures comprised of oligonucleotides (1 µg), 1 X T4 ligase buffer
(Promega M1801), and T4 polynucleotide kinase (NEB M0201S). The reactions were incubated
at 37 ℃ for 1 hr in a water bath and heat inactivated at 65 ℃ for 20 minutes in a water bath.
Twenty microliters of each phosphorylated oligonucleotide were then combined, and the mixture
was incubated at 95 ℃ for 5 minutes in PCR machine, then ramped to 24 ℃ at 1.5 ℃/minute
that resulted in the double-stranded gRNA cassette.
The double-stranded DNA containing the crRNA gene, was ligated into the vector. A
15:1 (insert:vector) molar ratio was calculated utilizing the NEBioCalculator. Two hundred ng of
dephosphorylated crRNA backbone, annealed oligos, 1 X ligation buffer (Promega M1804), and
1 µL of rapid DNA ligase (ThermoFisher Scientific K1422) were filled to 10 µL total volume.
Reactions were incubated at room temperature for 15 minutes. The resulting plasmids were
transformed into Competent DH5 cells for amplification.
Transformation. For transformation, 5 µL of ligation reaction was mixed with 50 µL of
Competent DH5α cells (Thermofisher Scientfic 18258012), incubated on ice for 30 minutes, and

31

heat shocked at 42 ℃ for 35 seconds via bead warmer. Five-hundred µL of Luria Broth was
added, and mixtures were incubated in incu-shaker at 37 ℃ at 200-220 rpm for 1 hr. Full
mixtures were plated on Luria Broth and 1 µg/mL ampicillin plates and incubated overnight in
VWR 1540 incubator at 37 ℃ overnight.
Plasmid screening. To be ensure our gRNA genes were correctly inserted into crRNA
backbone plasmids, the colonies from the transformation were screened for the presence of the
crRNA gene by colony polymerase chain reaction (PCR) (Green and Sambrook, 2019). PCR
reactions were made in PCR tubes were filled to 20 µL and comprised of 1 X DreamTaq Green
Mastermix (Thermofisher Scientific K1082), M13 reverse primer, and 100 pg/µL CAPS1 premRNA-targeting antisense (oRU 64) or CAPS1 mRNA-targeting antisense (oRU 63). Individual
colonies were randomly picked and simultaneously resuspended in double-distilled water within
individually marked PCR tubes and streaked onto labeled locations on an LB with 1µL/mL
ampicillin plate. The remaining reagents for PCR were added to the bacteria suspension, and the
PCR reactions were cycled in the conditions listed in Table 2. Five microliters of each PCR
reaction were subject to Bluegel electrophoresis (according to Minipcr). Colonies corresponding
to 500 bp PCR product compared to 100 bp GeneWiz ladder were isolated from the streaked
plates and the plasmid DNA isolated via Wizard midiprep kit. Plasmids were stored at -20 °C
prior to transfection within INS-1 cells.

Thawing INS-1 Cells
To use REPAIR to modify RNA editing frequency within CAPS1, the INS-1 cell line was
obtained from liquid nitrogen storage and thawed to 37 ℃ via water baths, pipetted into 15 mL
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Table 1: Oligonucleotides Used in This Study
Name

oRU

Sequence

CAPS1

oRU 48

AATGATCACACTTTTGGTGGCAAAGTTTG

oRU 49

CTGTCCTTCATGCTGATACCTTGTAAG

oRU 50

ATTAGAATTCTATTTGTGCCCCGTCTGG

oRU 51

CAACCGATCAAACGCAATGTT

CAPS1 premRNA sense

oRU 61

CAACGATGTCCTTCGTGATAAGGTCAATGAGGAGAT
GTATATAGAAAGGTTATTTGATGTC

CAPS1 premRNA antisense

oRU 64

CAACGATGTCCTTCGTGATAAGGTCAATGAGGGGAT
GTATATAGAAAGGTTATTTGATGTC

CAPS1 mRNA
sense

oRU 62

CAACGATGTCCTTCGTGATAAGGTCAATGGGAGATGT
ATATAGAAAGGTTATTTGATGTCAATC

CAPS1 mRNA
antisense

oRU 63

CAACGATGTCCTTCGTGATAAGGTCAATGGGAGATGT
ATATAGAAAGGTTATTTGATGTCAATC

M13 Reverse

M13R

AGCGGATAACAATTTCACACAGG

2c minigene

Table 2: Thermocycler Conditions for Colony PCR
Step

Temperature, ℃

Time

# of Cycles

Initial denaturation

95

3 min

1

Denaturation

95

30 s

Annealing

50

30 s

Extension

72

1 min

Final Extension

72

10 min
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1

conical tubes filled with 10 mL 37 ℃ media (ThermoFisher Scientific 118750854; media recipes
outlined in Table 3), and transferred drop-wise via 25 mL pipette to 10 cm Falcon plates
containing 5 mL of warm media. Plates were incubated at 37 ℃ with 5 % CO2 for 3 hours, then
aspirated and replaced with new media. Three mL of media was added to INS-1 cells every few
days for 2 weeks until cells were adhered to the plate.

Table 3: INS-1 cell media
Ingredients mixed with RPMI 1640

Concentration

10% Heat inactivated Fetal Bovine Serum
1% Penicillin/Streptomycin
Na Pyruvate

1 mM

HEPES

10 mM

2-mercaptoethanol

50 µM

INS-1 Cell Transfection
When INS-1 cells become overcrowded, cell growth stunts. To aid cell division, cells
require passaging into new plates with room to grow. INS-1 cell growth slows at 80-85 %
confluence and therefore needs passage. Full media volume (~10 mL per 10 cm2 dish) was
transferred to a 15 mL conical tube and centrifuged (Sorvall Legend X1R) at 50 x g for 5
minutes. While centrifuging the media, cells were trypsinized and incubated in the CO2 incubator
at 37 ℃ for 10 minutes. The cells were disrupted by pipetting up and down and the suspension
distributed equally to 6 wells in a 6-well plate to prepare for transfection. These wells received
1:1 ratio of old, centrifuged (conditioned) media to fresh media.
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Cell transfections are most successful during active cell division. To make sure cells
were in division and to give them time to recover from passaging, cells were incubated for ~24
hrs. Cell media was aspirated, replaced with warm 37 °C RPMI only, and placed in the CO2
incubator while transfection mixtures were made. These transfection mixtures were made in
microcentrifuge tubes by mixing 250 µL of RPMI only, 3 µg of DNA (or increasing amounts of
3, 5, and 7 µL for transfections in Table 4), and 17 µL of polyethylenimine (PEI) (Longo,
Kavran, Kim, and Leahy, 2013) or 7.5 µL TransIT-2020 (TI; Mirus MIR 5400). After incubation
at room temperature for 30 minutes, the transfection mixture was added to the 6-well plates
(according to Table 4-8 schemas) and incubated for 24-72 hours. Cells that were transfected with
YFP and either PEI or TI were incubated for varying hours to determine optimal incubation time
for peak YFP fluorescence. Statistical analyses of transfections were performed by One-Way
ANOVA and multiple comparisons. Statistical error of the mean was calculated by calculating
cohort standard deviation and dividing by square root of the sample size (n).
REPAIR transfection. To investigate whether CAPS1 editing frequencies could be
manipulated by REPAIR, INS-1 cells were transfected with cDNA encoding for Cas13-ddADAR
(pRU 86, Addgene 103849) and one of three possible gRNA-expressing vectors (Table 5):
Targeting CAPS1 pre-mRNA (pRU 89; cloned from Addgene 103854), targeting CAPS1 mRNA
(pRU 90; cloned from Addgene 103854), or a non-targeting (negative control) gRNA (pRU 88,
Addgene 103868).
ADAR1p150 transfection. To investigate whether increasing amounts of ADAR1 cDNA
endogenously altered RNA-editing of CAPS1 transcript, cells were given varying amounts of
plasmids containing ADAR1p150 (pRU 20; generously gifted from Ronald B. Emeson,
Vanderbilt University, made by Jennifer Hood; scheme listed in Table 6). A plasmid expressing
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the serotonin receptor type 2c (5HT2C) minigene (pRU 58; generously gifted from Ronald B.
Emeson) was used as a control.
Overexpression of CAPS1 isoforms. Alternative to increased expression of ADAR and
REPAIR, cells were given cDNA (Table 7) encoding fluorescently-tagged proteins including
phogrin-mCherry (pRU 51, generous gift form David Piston), AcGFP (pRU1, Clonetech), NPYYFP (pRU 54, generous gift from Ronald Emeson), and/or CAPS1-GFP (pRU 48 and pRU 49).
Plasmids encoding edited Caps1 (pRU 28) and non-edited Caps1 (pRU 29; Table 8) isoforms
were transfected to manipulate editing ratios. Cells were incubated for 60 hrs post-transfection.

Table 4: PEI and TransIT-2020 Transfection
Wells

Transfection Contents

1 and 2

Non-transfected

3

PEI only

4

PEI and YFP

5

TI

6

TI and YFP

Table 5: CAPS1 REPAIR Transfection
Wells

Transfection Contents

1 and 4

Cas13-ddADAR and non-targeting gRNA

2 and 5

Cas13-ddADAR and gRNA 1

3 and 6

Cas13-ddADAR and gRNA 2
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Table 6: ADAR1p150 Transfection
Wells

Transfection Contents

1 and 4

3 µg 2c minigene

2 and 5

5 µg ADAR1p150 and 3 µg 2c minigene

3 and 6

7 µg ADAR1p150 and 3 µg 2c minigene

Table 7: Fluorescently-tagged Secretagogue Transfection
Wells

Transfection Contents

1 and 2

Non-transfected

3

YFP

4

Phogrin-mCherry

5

NPY-GFP

6

Phogrin-mCherry and NPY-GFP

Table 8: CAPS1 Isoforms and NPY-GFP Transfection
Wells

Transfection Contents

1 and 2

Blank cells

3

Non-transfected (TI only)

4

NE-CAPS1 and NPY-GFP

5

E-CAPS1 and NPY-GFP

6

NPY-GFP
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RNA Isolation from INS-1 cells
To see if REPAIR or increased ADAR expression modified editing frequency within
CAPS1, we needed to convert CAPS1 RNA into cDNA and Sanger sequence. RNA from all
transfected cells (Tables 5 and 6) was isolated by adding 200 µL of Trizol (Tri reagent; Ambion
Life Technologies 15596026) to each of the wells in the 6-well plate. The mixture was
transferred to labeled 1.5 mL microcentrifuge tubes containing 40 µL of Chloroform. Following
vortexing and centrifugation according to Sigma Aldrich Trizol RNA isolation protocol, the
aqueous solution was transferred to a microcentrifuge fresh tube. To further purify the RNA, an
additional 200 µL of Tri reagent and 40 µL of Chloroform were added to the RNA solution in a
new tube. Samples were vortexed and centrifuged for 5 minutes, the aqueous solution transferred
to a new tube. Precipitation of RNA was accomplished by adding equal volume 95 % room
temperature ethanol. The pellet was washed with 70% ethanol. The dried pellet was resuspended
in 50 µL house-made RNase-free water.

RT-PCR
RNA was converted into cDNA and the area surrounding the CAPS1 editing site was
amplified in order to determine editing of the transcript. Utilizing the High-Capacity cDNA
Reverse Transcription (RT) kit (Applied Biosystemsms 4368814), 0.5 – 1 µg of RNA, 1 X RT
buffer, 1 X RT random primers, 0.5 X dNTPs, 1 µL RT, and 0.5 µL RNasin (Promega A7973)
were filled to 20 µL and placed in the thermocycler at 25 °C for 10 minutes, 37 °C for 1 hr, and
85 °C for 5 minutes. A control RT reaction was also performed for each sample that lacked RT.
Five µL of each RT-PCR reaction, 1 X DreamTaq Master Mix (Thermo Scientific K1071) and
400 ng of oRU 48 and oRU 49 (seqeunces listed in Table 1), were used in each PCR reaction. A
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negative control lacking any RT-PCR was used as a no-template control. Volumes were filled to
50 µL and cycled under the conditions listed in Table 9.

Table 9: CAPS1 Thermocycler Conditions
Step

Temperature, ℃

Time

# of Cycles

Initial denaturation

95

5 min

1

Denaturation

95

30 s

Annealing

57

30 s

Extension

72

35 s

Final Extension

72

10 min

32
1

Analyzing CAPS1 RNA Editing Frequency
RT-PCR samples were sent to GeneWiz (South Plainfield, NJ) for purification and
Sanger sequencing. Editing frequency for the E/G site was determined from the
electropherogram traces. The sum of the area under both the A peak and G peak (inosine) were
calculated using ImageJ (https://imagej.nih.gov/ij/download.html). The inosine peak was then
divided by the sum of the areas under the curve to determine percent of edited (black peak) RTPCR products.

Stimulating INS-1 Cells
To understand how LDCV secretion is affected by CAPS1 edited and non-edited isoforms, INS-1
cells needed to be stimulated for LDCV secretion and then measured. Since a fluorescence
reader (SpectraMax) was used to measure secretion, the normal RPMI containing phenol-red was
replaced with clear DMEM. Additionally, since we were measuring both basal and stimulated
secretion, we used glucose-free media so glucose concentrations could be manipulated. Phenol
red-free and glucose-free DMEM (Gibco A1443001) and glucose were mixed to 2 mM and 16.7
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Table 10: Plasmid reference list
Experiment
REPAIR

Construct

pRU

Purpose

Cas13ddADAR

86

Manipulate RNA editing frequency of CAPS1

crRNAbackbone

87

For cloning of gRNA

gRNA1

89

Target REPAIR to CAPS1 pre-mRNA

gRNA 2

90

Target REPAIR CAPS1 mRNA

Non-targeting
gRNA

88

Negative control for REPAIR

Cas13

91

CAPS1 knockdown

20

Increase Editing Frequency of CAPS1

58

Transfection control

28

Increase edited CAPS1 within INS-1 cells

Non-edited
CAPS1

29

Increase non-edited CAPS1 in INS-1 cells

YFP

52

View transfection

NPY-GFP

53

Secretagogue

PhogrinmCherry

51

Secretagogue

Overexpression ADAR1p150
of ADAR
2c minigene
Overexpression Edited CAPS1
of CAPS1

Secretion

mM glucose solutions to make basal and secretion media, respectively. NPY-YFP (pRU 54) and
non-tagged CAPS1 (pRU 28 and pRU 29; Table 8) transfected cells were incubated with 2 mM
glucose basal media for 2 hrs. The media was removed and transferred to chilled microcentrifuge
tubes, centrifuged, then transferred to a new 6-well plate, and the fluorescence analyzed with
SpectraMax plate reader (wavelengths listed in Table 11). Fluorescence was read by the
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SpectraMax “fluorescence” measurement tool. Full area of each well of the 6-well plate was read
with a point density of 7 nm. Following measurement, media was then replaced with 16.7 mM
glucose secretion media. After 2 hours, secretions (media) were then transferred to a new 6 well
plate and fluorescence was read on the SpectraMax. The SpectraMax fluorescence options and
set-up was tailored to a 6-well clear bottom plate with reading density ~7. Following readings,
the same cells were harvested in 200 l of Trizol and stored at -80 °C. Basal secretion was
subtracted from stimulated secretion to find total glucose-stimulated secretion fluorescence.
Fluorescence between edited and non-edited CAPS1 and NPY-GFP were analyzed for
significance via One-way ANOVA followed by multiple comparisons.

Table 11: Excitation and Emission of Fluorescently-tagged Proteins and Secretagogues
pRUs

Fluorescent Tag

Excitation (wv)

Emission (wv)

pRU 1

YFP

485 nm

535 nm

pRU 51

mCherry

554 nm

620 nm

pRU 48, 49, 54

GFP

395 nm

509 nm
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RESULTS
Our goal was to manipulate RNA editing frequency and analyze how altering the editing
frequency of CAPS1 mRNA, and ultimately the ratio between edited and non-edited Caps1
protein, affects INS-1 secretion. INS-1 cells predominantly express unedited Caps1, so
increasing CAPS1 editing was attempted with CRISPR-Cas13-ddADAR, a system incorporated
with a catalytically inactive Cas13 protein fused with a hyperactive ADAR deaminase domain
(Cas13-ddADAR). This system relies on tracrRNA and unique crRNA to target Cas13-ddADAR
to the CAPS1 E/G editing site (Cox et al., 2018; Figure 7). The tracrRNA contains a long stretch
of nucleotides that form a loop bound by the inactive Cas13 nuclease. The tracrRNA is fused to
the crRNA and delivered by the Cas13b-crRNA backbone plasmid while the deactivated Cas13
is expressed via a separate vector (Cox et al., 2018; Figure 8).

Figure 7. Using CRISPR/Cas13-ddADAR to manipulate RNA editing of CAPS1
transcripts. Catalytically inactive Cas13 is fused with ADAR2 hyperactive deaminase domain
(ADAR). The gRNA specifies the target adenosine nucleotide by hybridizing with the editing
region of the transcript. This brings Cas13-ADAR close to the adenosine (A) targeted for editing.
The cytosine (C) directly across from the A promotes adenosine deamination into inosine (I) of
the mismatched adenosine.
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Figure 8. The vector utilized to clone CAPS1 oligonucleotides and CRISPR RNA to form
vectors containing CAPS1 gRNA1 and CAPS1 gRNA2. Plasmid characteristics include the
origin of replication used for DH5α cells (Ori, yellow arrow), a gene encoding ampicillin
resistance (green arrow) for selective pressure, a U6 promoter (white arrow) for transcription of
the gRNA in INS-1 cells. The locations of primers utilized for PCR-based clone screening are
identified by purple arrows (Addgene 103854).
To make the crRNA unique to the CAPS1 E/G site, two crRNAs were designed targeting
CAPS1 pre-mRNA (gRNA 1) and CAPS1 mRNA (gRNA 2). Each gene for the crRNA was
made by annealing two strands of complementary oligonucleotides and cloning this 30
nucleotide-long cassette into the Cas13b-crRNA backbone. The resulting full gRNA gene will be
expressed from the U6 promoter, a RNA Polymerase III promoter (Kunkel, Maser, Calvet, and
Pederson, 1986). Following transcription, the gRNA will bind to the targeted CAPS1 region. The
nucleotide directly across from the E/G site will not be complementary to the A targeted for
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deamination. Instead, the nucleotide directly across from A is C, as crRNA with this specific
structure increases editing frequency by Cas13-ddADAR (Qu et al., 2019).
Screening Plasmids for Gene Insertion
The crRNA gene was ligated into the crRNA backbone and transformed into bacterial
cells. Clones were screened for the presence of the gRNA gene via colony PCR where the
primers bind to the backbone as well as the crRNA cassette itself. PCR products of 487 bp
(gRNA1) or 490 bp piece of DNA (gRNA2) were amplified and indicated colonies contained a
clone with the CAPS1-targeting crRNA gene. gRNA 1 gene was cloned in all five, or 100%, of
screened colonies, as indicated by the presence of 487 bp bands (Figure 9A). Six colonies were
screened for gRNA 2 gene and five, or 83%, of the clones were positive and therefore had the
expected 490 bp band (Figure 9B). One positive clone containing each of the 487 or 490 bp PCR
product was isolated. Purified plasmid DNA containing Cas13-ddADAR and plasmid containing
gRNA1 or gRNA 2 genes were transfected into INS-1 cells to test the ability to manipulate RNA
editing of CAPS1.

Figure 9. Screening for gRNA positive clones. Colony PCR of CAPS1 gRNA 1 (A) and
CAPS1 gRNA 2 (B) cloned into the CRISPR crRNA backbone. The products were separated by
agarose gel electrophoresis. The expected 487 bp (gRNA 1) and 490 bp (gRNA 2) products are
indicated by a black arrow. (A) The lanes 1-5 contain PCR products from gRNA 1 screening.
100 bp ladder (L) is in the right lane. (B) PCR products screened for gRNA 2 in negative control,
water only lane 1 and colonies lanes 2-6. 100 bp ladder (L) is in the right lane. Primer dimers are
observed below PCR products and indicated by a white arrow in both gRNA 1 (A) and gRNA 2
(B) figures.
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INS-1 Cell Transfection Results
INS-1 cells are difficult to transfect. In order to assure that the plasmids for REPAIR
could be delivered to the cells, we tested for a reliable transfection method. The transfection
efficiencies of two different transfection reagents, PEI and TransIT-2020, were compared against
one another using cellular fluorescence after transfection of a YFP expressing vector. Relative
fluorescence of cells transfected with a YFP-expressing vector using PEI was comparable to both
PEI and TransIT-2020 negative controls (Figure 10). However, average fluorescence for
TransIT-2020 was 13,000 RFU, approximately 10,000 more RFU than PEI transfection of the
same YFP vector (Figure 10). TransIT-2020 was used for all assays, thereafter.
We also tested the optimal time for fluorescent detection after transfection. RFU from
cells was measured 24, 36, 45, 60, and 72 hr after transfection of YFP with TransIT-2020. As
expected, YFP RFU was comparable among PEI and YFP and negative controls. YFP RFU
using TransIT-2020 peaked 60 hrs post-transfection (Figure 11). Therefore, cells were incubated
60 hrs before secretion experiments.

Comparing INS-1 Secretion Efficiency of Different Fluorescently-tagged Secretagogues
To accomplish our goal of understanding how edited CAPS1 affects LDCV secretion, we
needed to efficiently measure secretion of secretagogues from INS-1 cells. NPY is a
neuroprotein secreted primarily by neurons, but is also highly expressed and secreted by INS-1
cells (Waeber et al., 1993) while phogrin is considered a transmembrane protein that associates
with LDCVs in regulated secretion (Caromile, Oganesian, Coats, Seifer, and Bowen-Pope,
2010). We had fluorescently-tagged versions of each of these proteins available to us, therefore
each were tested for their ability to be detected and secreted from INS-1 cells.
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We first tested whether we could detect NPY-GFP and phogrin-mCherry in INS-1 cells
post transfection. Sixty hours post-transfection with plasmids expressing each fluorescent
protein, phogrin-mCherry and YFP RFU were barely detectible, while NPY-GFP RFU (~60,000
RFU) was much greater in INS-1 cells (Figure 12). This data suggests that NPY-GFP is more
detectible in cells than phogrin-mCherry.
Fluorescence was expected to be detectable in the media if the secretagogues are secreted
from the cells. YFP (control, not-secreted), Phogrin-mCherry, and NPY-GFP secretion were
compared to determine which protein was secreted more efficiently from INS-1 cells. Following
stimulation for 2 hrs with 16.7 mM glucose, YFP and phogrin-mCherry RFU in the media were
comparable to the negative control, while NPY-YFP in media was significantly greater at
~30,000 RFU (Figure 13). These results suggested that NPY-YFP was more efficiently
efficiently secreted by INS-1 cells. Therefore, NPY-GFP was used as the secretagogue in further
experiments.
CAS13-ddADAR Directed Editing of CAPS1 Transcripts
Once optimal transfection reagents and secretagogues were determined, we aimed to
modify editing frequency of CAPS1. Introducing Cas13-ddADAR with the CAPS1 targeting
gRNA was expected to increase editing of CAPS1, therefore increasing the detected ratio of
edited to unedited CAPS1. INS-1 cells were transfected with plasmids containing Cas13ddADAR cDNA and genes for gRNA 1, 2, or the non-targeting control gRNA (negative control).
RNA was isolated from the transfected cells and the editing region of CAPS1 was amplified by
RT-PCR and sequenced with the Sanger method (Figure 14). The characteristic A/G double
peak was seen at the E/G editing site in each sample. Editing levels were estimated based on the
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Figure 10. Relative fluorescence post-transfection with PEI and TransIT-2020. INS-1 cells
were transfected with YFP using PEI and TransIT-2020 (N = 2, n = 4). YFP relative
fluorescence units (RFU) were measured in cells transfected with YFP using PEI (YFP and PEI)
or using Transit-2020 (YFP and TI). Negative controls were mock transfected (PEI and TI only).
ANOVA, p = 0.002*. Error bars indicate standard error of the mean (SEM).

16000
14000
12000
10000
8000
6000
4000
2000
0
24

36

48

60

72

Hours
PEI

PEI + YFP

TI

TI + YFP

Figure 11. Relative cellular YFP fluorescence post-transfection. INS-1 cells were transfected
with YFP (N = 3). Relative fluorescence (RFU) was measured from YFP and PEI, YFP and
TransIT-2020 (TI), and negative controls at 24 -72 hours post-transfection. Error bars indicate
SEM.
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Figure 12. Relative fluorescence in INS-1 cells following transfection. INS-1 cells were
transfected with GFP, NPY-YFP, or Phogrin-mCherry and the fluorescence of the cells was
determined. Negative control cells (grey) were mock transfected and read at the same
wavelengths as the experimental group (N = 3). ANOVA, p > 0.05. Error bars indicate SEM.

35000
*

30000

RFU

25000
20000
15000
10000
5000
0
YFP

NPY-GFP

Phogrin-mCherry

Figure 13. Relative fluorescence in media following glucose stimulation of INS-1 cells. INS1 cells (N = 3) were treated with 16.7 mM glucose. Fluorescence in secreted media from NPYGFP, YFP, and phogrin-mCherry transfected cells (blue) were read and compared against Mock
transfected negative controls (gray). ANOVA followed by multiple comparisons, *p = 0.002.
Error bars indicate SEM.
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The area under the curves for nucleotides A (non-edited, genomically encoded) and G (edited).
INS-1 cells transfected with Cas13-ddADAR plus gRNA1, gRNA2, or a control gRNA had an
editing frequency of 15 %, 13 %, and 16 %, respectively (Figure 15). Since editing frequencies
were similar in experimental and control groups, the ratio between edited and non-edited CAPS1
were not manipulated via Cas13-ddADAR.
Since there were no observed differences in editing frequencies between experimental
and control cells transfected with Cas13-ddADAR, an alternative method was used to manipulate
RNA editing of CAPS1 in INS-1 cells. Experimental cells were transfected with a plasmid that
expresses ADAR1p150 cDNA and compared to non-transfected controls to determine if
overexpression of the enzyme responsible for CAPS1 RNA editing could increase the level of
CAPS1 RNA editing in INS-1 cells. RNA was isolated from transfected cells and the editing
region of CAPS1 RNA was amplified via RT-PCR and subjected to Sanger sequencing (Figure
14). INS-1 cells transfected with ADAR1-p150 had an editing frequency of 18% compared to the
control which has 24% editing (Figure 16). There were no significant differences in editing
between the control and experimental groups, thus CAPS1 editing frequency was not influenced
by ADAR1p150 overexpression.
Since neither method to manipulate editing of endogenous CAPS1 mRNA was
successful, we shifted to an alternative method to modify the ratios of edited to non-edited
CAPS1. In this model, we overexpressed CAPS1 edited and non-edited isoforms from cDNA
containing constructs. Expressing edited CAPS1 will increase the proportion of edited CAPS1
within the cell. The change to editing was expected to be small considering CAPS1 is robustly
expressed from the INS-1 genome. We attempted to measure RNA editing from these cells to
provide an exact estimate of CAPS1 editing frequency, but the RT-PCR failed due to degradation
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of the RNA in the samples. While the degree of RNA editing frequency within CAPS1 is
unknown, we proceeded with further experiments under the assumption that editing frequencies
were altered, if only slightly.

Figure 14. Determining CAPS1 RNA editing levels. To determine RNA editing levels of
CAPS1 mRNA, total RNA was isolated from cultured cells then subjected to reverse
transcription. The resulting cDNA was amplified through PCR and sequenced with Sanger
sequencing. To calculate the editing frequency, the area under the G peak (resulting from edited
transcripts) was divided by the total area of both A and G peaks at the editing site (boxed).
Stimulated and Basal Secretion
Once we decided on a model to manipulate RNA editing frequency of CAPS1, we
proceeded to address our second aim to measure basal and stimulated secretion. After
overexpressing edited and non-edited CAPS1 cDNA in INS-1 cells, cells were treated with low
glucose to provide conditions for basal secretion of NPY-GFP. After correcting for transfection
and expression of NPY-GFP in the cells, the basal NPY-GFP secretion from cells also containing
excess non-edited CAPS1 was significantly decreased (p = 1.9 x 10-6) compared to those
transfected with edited CAPS1 and NPY-GFP only (Figure 17). The same cells were then treated
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Figure 15. RNA editing of CAPS1 by Cas13-ddADAR. INS-1 cells were transfected with
Cas13-ddADAR and gRNAs. Total RNA was isolated and CAPS1 mRNA was amplified via RTPCR. Samples containing Cas13-ddADAR gRNA 1 (A) and Cas13-ddADAR gRNA 2 (B) were
subjected to Sanger sequencing and compared to a non-targeting (nt) gRNA (C). Sanger
sequencing electropherogram traces of the RT-PCR products are shown. CAPS1 E/G editing site
(blue box) contains both adenosine (green peak) from non-edited transcripts and guanosine
(black peak) from edited transcripts. The genomically encoded sequence is shown below each
sequence trace.
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Figure 16. RNA editing of CAPS1 in INS-1 cells by ADAR1p150. INS-1 cells were
transfected with a plasmid expressing ADAR1p150 cDNA (A) and compared against mock
transfection (B). Electropherogram traces from Sanger sequencing of the RT-PCR products are
shown. The CAPS1 E/G editing site (blue box) depicts adenosine (green peak) from non-edited
transcripts and guanosine (black peak) from edited transcripts. The genomically encoded
sequence is indicated below each sequence trace.

with high glucose (16 mM) to induce GSIS. Glucose stimulated secretion was measured by
determining the increase in NPY-GFP secretion under stimulated conditions over the basal
conditions. The results indicate inconsistent levels of secretion in all groups. At times, the level
of secretion in stimulated cells was less than the basal secretion (resulting in negative glucose
stimulated secretion levels, Figure 18). There were no statistical differences in stimulated
secretion between cells expressing non-edited or edited CAPS1.
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Figure 17. NPY-GFP Fluorescence Following Basal Secretion from INS-1 cells. INS-1 cells
(N = 3, n = 6) were transfected with NPY-GFP and edited (E) or non-edited (NE) CAPS1. Secretion
was compared to the cells containing only NPY (tagged with GFP and with no CAPS1 transfected).
Error bars indicate SEM. ANOVA, *p = 1.9 x 10-6.

Glucose Stimulated
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Figure 18. Stimulated secretion of NPY-GFP from INS-1 cells. INS-1 cells (N = 3, n = 6)
were transfected with NPY-GFP and edited (E) or non-edited (NE) CAPS1. Secretion was
measured after 2 hrs in 16mM glucose. Basal secretion from the same cells was subtracted from
the stimulated secretion to determine glucose stimulated secretion. ANOVA, p > 0.05.
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DISCUSSION
CAPS1 facilitates stimulated cell secretion by bridging LDCVs and the plasma
membrane. RNA editing occurs within the CAPS1 pre-mRNA, an event highly conserved across
mammals (Miyake et al., 2016). This event recodes the transcript, substituting a glycine for a
glutamic acid residue within the region of the protein that interacts directly with the vesicle. PC12 cells expressing only edited CAPS1 demonstrate increased LDCV secretion (Miyake et al.,
2016), suggesting that the role of CAPS1 RNA editing is to upregulate secretion.
RNA editing only occurs in about 20 % of CAPS1 transcripts. Studies in cultured neurons
showed that even slight increases in editing frequency significantly modify secretion efficiency
of SVs (Ulbricht et al., 2017). We used a similar method of increasing levels of edited or nonedited CAPS1 in insulinoma cells. We found that basal, or non-stimulated, secretion levels from
LDCVs were significantly affected by changes in CAPS1 editing while the effect of CAPS1
editing on stimulated secretion was inconclusive.

Manipulating RNA Editing Frequency Within the CAPS1 Transcript
To study the effects of CAPS1 RNA editing on LDCV secretion from the insulinoma
(INS-1) cells, we first sought to alter the level of CAPS1 editing within INS-1 cells. Since INS-1
cells express primarily non-edited CAPS1, we attempted to increase editing of the endogenous
CAPS1 by simply administering exogenous ADAR1. If CAPS1 RNA editing is limited by the
amount of ADAR1 available within the cell, then transfecting cells with excess ADAR1 should
upregulate editing. However, increasing ADAR1 levels within INS-1 cells did not affect editing
frequency within the CAPS1 transcript (Figure 16). This indicates that CAPS1 RNA editing is
not wholly dependent upon ADAR1 levels. It is relatively well known that ADAR expression
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levels weakly correlate with RNA editing events. Regardless of ADAR expression levels RNA
editing targets, like GluR-2 and 5HT2c , are edited consistently (Jacobs et al., 2009). Additionally,
interferon-induced upregulation of ADAR1 levels throughout the body, do not have a significant
effect on editing within ADAR targets in the brain (Hood et al., 2014).
We also attempted to increase the level of editing within the endogenous CAPS1 transcript
by targeting Cas13-ddADAR to the E/G site (Figure 7). This REPAIR system requires a gRNA
that will target Cas13-ddADAR to the desired editing location. We made two different guide
RNAs: gRNA1 targeted CAPS1 pre-mRNA by recognizing parts of both exon 28 and a
downstream intron. gRNA2 complements a region from exons 28-29 within the mRNA.
Following successful cloning of the gRNA gene (Figure 9), we transfected the plasmids
expressing the gRNA with Cas13-ddADAR into INS-1 cells. The results show that REPAIR did
not increase RNA editing frequency within CAPS1 pre-mRNA and mRNA (Figure 15). This
failure may be attributed to the double-stranded nature of CAPS1 pre-mRNA and mRNA. The
pre-mRNA is known to form a dsRNA duplex via complementary regions surrounding the
editing site and in the downstream intron. This duplex is the structure recognized by ADAR1 for
RNA editing (Miyake et al., 2016). Similarly, a region of the CAPS1 mRNA containing the
editing site is predicted to form an imperfect dsRNA structure by binding to a region within the
3’UTR (Figure 19). Since Cas13 requires single-stranded substrates (Cox et al., 2016.), it is
possible the double-stranded CAPS1 structures prohibited Cas13 interaction with the CAPS1
mRNA.
We were unable to manipulate editing of endogenous CAPS1 transcripts, so we shifted
our attention to altering editing by expressing CAPS1 edited and non-edited variants with cDNA
constructs. Overexpressing CAPS1 isoforms creates an artificial situation where we are both
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adding CAPS1 and altering ratios of edited to non-edited CAPS1. Ideally, we would not increase
(or decrease) the amount of CAPS1 in the cells, but instead, replace the mostly non-edited
CAPS1 with desired ratios of edited to non-edited CAPS1, allowing us to see how editing alone
affects secretion. One way to do this would be to first knock down CAPS1 mRNA, then express
CAPS1 isoforms using the cDNA clones. CAPS1 knockdown could be accomplished by using
catalytically active Cas13 and a gRNA complementary to CAPS1. Students in BMS 525 and
BMS 625 (Fall 2020) showed that Cas13 can knockdown CAPS1 using gRNAs targeting various
exons. In these experiments, gRNAs targeting exons 3, 4, and 31 were successful in the
knockdown of CAPS1 mRNA (data not shown). This experiment will need slight modifications
to be useful in manipulating CAPS1 editing. First, the gRNA must target the 3’UTR of
endogenous CAPS1. The cDNA clones expressing CAPS1 variants do not contain the
endogenous 3’UTR, so gRNA complementary to this location would allow us to target only the
endogenous CAPS1, while simultaneously expressing the desired CAPS1 variant from the cDNA
clone. From there, editing frequencies and editing-dependent secretion from INS-1 cells could be
analyzed by the methods outlined in this study.
Our model to overexpress CAPS1 isoforms to modify RNA editing frequency also leads
to increased total expression of Caps1. It is possible the overexpression of CAPS1 could
confound results and possibly occlude conclusions regarding RNA-editing dependent effects.
One study replaced CAPS1 with solely the edited variant and showed significant differences
between secretion from LDCVs (Miyake et al., 2016). However, this model also has limitations
in assessing how natural variations of CAPS1 editing affect its role in secretion. Since only about
20 % of CAPS1 transcripts are edited, it is unrealistic to expect CAPS1 editing to increase to 100
% within an organism or tissue of an organism. More reasonably, natural conditions, such as
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disease, may only slightly alter editing. Inflammation, a common symptom of disease, increases
A-to-I editing occurrences up to 5 % in lymphocytes (J. H. Yang et al., 2003). We expect our
model to be more physiologically relevant and resemble this slight modification to RNA editing
frequency.
Similar overexpression of edited CAPS1 in neurons, where CAPS1 editing was only
increased by 5 %, showed measurable effects on secretion from SVs (Ulbricht et al., 2017). We
were unable to determine the exact ratio of editing in our transfected cells. We isolated RNA
from the INS-1 cells used in our study and attempted to analyze the change in overall CAPS1
editing levels but the RT-PCR was unsuccessful due to unstable RNA. This information may be
crucial to determine the role of editing in our experiments: If differences in CAPS1 editing
frequency are not detectible between the transfected and non-transfected groups, then perhaps
effects on secretion are limited. Thus, the lack of phenotype may be due to the lack of our
influence on editing ratios, rather than a general lack of RNA editing-dependent effects on Caps1
function in LDCV secretion form INS-1 cells.
We believe this model will provide insight into how RNA editing alterations that result
from disease, or treatment of disease, affect secretion from LDCVs. For example, a common
treatment for patients with Hepatitis C includes interferon treatments (Rong and Perelson, 2010).
The interferon induces ADAR1p150 transcription (Hood et al., 2014). If this ADAR1p150
induction increases editing of CAPS1 by as little as 5 %, it can potentially affect secretion
Previous work investigating the connection between ADAR1p150 and RNA editing have
focused on the brain and found no significant alterations to RNA editing (Hood et al., 2014).
Preliminary data within Dr. Ulbricht’s lab suggests that inflammation and ADAR1p150
induction does have a slight effect on CAPS1 editing in peripheral tissues (data not shown). Our
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work aims to investigate if small changes in CAPS1 editing frequency affect secretion from
LDCV vesicles.

Figure 19. Double-stranded structures of CAPS1 pre-mRNA and mRNA. CAPS1 pre-mRNA
forms a dsRNA structure via the E/G and ECS regions (A). It is predicted CAPS1 mRNA can
also form a dsRNA structure by complementary regions with exon 28 and section of the 3’ UTR
(B). The dsRNA structure is above each graphical representation of the transcript. Yellow arrows
depict the relative location of half of the duplex within the transcript and the red region
represents the E/G site. Shaded area represents the 3’ untranslated region.
CAPS1 Editing in Glucose Stimulated Secretion
With our model in place, next, we sought to determine how altered CAPS1 editing
levels affect secretion from LDCVs. NPY-GFP was detected in the cells after transfection and
was secreted into the media under high glucose conditions (Figure 13), suggesting that this
secretagogue was detectible and efficiently secreted. The NPY used in this study was tagged
with GFP. Moreover, instead of the full-length NPY, we used a peptide that only contained NPY
signal sequence, a segment (28 aa) of the full NPY (36 aa) that is packaged in LDCV and
secreted (El Meskini et al., 2001). NPY is known to be highly expressed and secreted by INS-1
cells (Waeber et al., 1993) and our work shows NPY-GFP we used is also loaded into and
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secreted from INS-1 cells (Figure 13). The other secretagogue tested, phogrin tagged with
mCherry, was barely detected in the cells or in the media (Figure 13). We believe the reason
Phogrin-mCherry emitted low levels of fluorescence was due to the close excitation and
emission wavelengths of mCherry (Table 11). It is possible that the SpectraMax plate reader
used to detect fluorescence from cells and media is more sensitive to GFP, a fluorescent peptide
with a larger range between excitation and emission wavelengths (Table 11).
After choosing an effective secretagogue, we attempted to stimulate secretion from INS1 cells. We expected increased edited CAPS1 to increase glucose stimulated secretion of NPYGFP from LDCVs, however, the data on stimulated secretion was inconclusive. In most of the
replicates, in all three groups (NPY only, NPY with non-edited CAPS1, and NPY with edited
CAPS1) NPY-GFP secreted during high glucose conditions was not more than during low (nonstimulating) glucose conditions, suggesting that INS-1 cells were not strongly stimulated by
glucose and glucose stimulated secretion did not occur (Figure 18). Future steps could focus on
using a more robust mechanism to stimulate secretion. Potassium generates a larger stimulus
than glucose and would likely result in total and efficient vesicle release. Using potassium as a
stimulus would shift the focus from glucose stimulated insulin secretion to LDCV stimulated
secretion, in general. This shift in focus would not significantly alter our goal to understand how
RNA editing within CAPS1 affects LDCV secretion and would be consistent with how
experiments in other LDCV secreting cells (namely, PC-12 cells) are done.
If future steps continue to assess glucose-stimulated secretion, it may be worth to
consider a different secretagogue. It is possible that NPY-GFP secretion is regulated differently
than endogenous insulin release. In fact, NPY negatively modulates insulin secretion by
interfering with adenylyl cyclase and decreasing ATP, which is required to trigger fusion of
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insulin granules in the RRP (Morgan et al., 1998; Wollheim and Sharp, 1981). The NPY
fragment used in our experiments encodes only the signal sequence, and it is unclear whether it
has similar effects on secretion compared to the full NPY peptide (Morgan et al., 1998). It may
be beneficial to bypass NPY-related potential complications by direct measurement of insulin
secretion. Commercially available ELISA kits (ThermoFisher # ERINS) can be used to measure
the amount of insulin in the media following glucose stimulation.

CAPS1 Editing and Basal Secretion
Glucose stimulated secretion is measured by subtracting secretion under low glucose
conditions (2 mM glucose) from secretion induced by high glucose conditions (16 mM glucose).
The levels of secretagogue in the media under low glucose (2 mM) conditions are a baseline
level of secretion that is not normally measured on its own, nor compared between experimental
conditions. Instead, this level of non-stimulated secretion is typically used as a constant, assumed
to be equal among all cells or conditions. We found basal stimulation to be significantly
decreased with non-edited CAPS1, even after accounting for the number of transfected cells
(Figure 17). This is interesting considering Ulbricht et al. (2017) also showed that altering
editing levels could affect spontaneous secretion from synaptic vesicles, but that stimulated
secretion was not affected. Miyake et al did not report non-stimulated secretion levels from PC12 cells with solely edited or non-edited CAPS1 but did find small differences between
stimulated secretion from these cells. Since the basal secretion is used in the calculations for
stimulated secretion, unaccounted for changes in basal levels could skew the results and lead to
mis-reporting alterations to stimulated secretion due to differences solely in basal secretion. This
leaves the possibility that, in Miyake et al. (2016) studies and our studies, the CAPS1 variants do
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not affect stimulated secretion from cells but edited and non-edited CAPS1 primarily regulates
basal secretion.
Increasing edited CAPS1 (to alter total editing by only 5 %) decreases synaptic vesicle
pool volume and increases sphericity of vesicle pool, suggesting that CAPS1 editing contributes
to a tighter, more compact pool of SVs in the synapse (Ulbricht et al., 2017). This study also
observed that edited CAPS1 decreases basal secretion from synaptic vesicles and non-edited
CAPS1 increases the same basal secretion (Ulbricht et al., 2017). In our experiments, edited
CAPS1 had no effect on basal LDCV secretion, but increasing non-edited CAPS1 levels resulted
in decreased basal secretion of LDCVs in INS-1. It is possible that the contrasting effects of
increasing non-edited CAPS1 between these studies are due to differences between mechanisms
of LDCV organization in INS-1 cells and SV in synapses. It is possible that CAPS1 does not play
the same role in vesicle organization for both vesicle types. To study INS-1 vesicle organization
and its dependency on CAPS1 editing, future studies could use a transmission electron
microscopy or 3-dimensional structure illumination microscopy (3D-SIM) to see how edited
CAPS1 affects the distribution of LDCVs. For example, 3D-SIM experiments would use
immunohistochemistry to visualize the location of vesicles within the cells and their dispersion
relative to each other and the plasma membrane. If this study shows non-edited CAPS1 in INS-1
cells results in more tightly clustered vesicles away from the membrane (similar to edited CAPS1
in synapses), CAPS1 organization capabilities may restrict secretion under non-stimulating
conditions by physically retaining vesicles in the RP. This would also indicate that CAPS1
editing-dependent effects on organization are dependent on the vesicle type and/or the cell type.
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The E/G Site: A Means of Modifying CAPS1 Function and Cellular Processes
One way that CAPS1 isoforms may differentially affect vesicle organization is through
CAPS1 interaction with vesicle and with itself. CAPS1 editing affects an amino acid within the
domain of the protein that directly interacts with vesicles. CAPS1 association with vesicles is
also required for homodimerization through its C2 domain (Petrie et al., 2016). This creates an
interesting model where CAPS1 may organize vesicles by linking them together through its
homodimerization (Figure 20). We do not understand how these two physical properties are
linked with RNA editing, but it is hard to ignore the possibility that RNA editing may affect
interaction with the vesicle and/or interaction with itself, thereby possibly affecting the overall
vesicle organization.

Figure 20. Model for Caps1-dependent vesicle organization. Caps1 homodimerizes via its C2
domain (green) and interacts with the vesicle through its LDCVBD (yellow). In this model,
Caps1 links vesicles together and organizes them in the interior of the cell. This may also restrict
vesicles in the reserve pool form moving toward the plasma membrane, where docking, priming
and fusion occur.
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It is possible that CAPS1 editing may affect secretion for some cell types differently than
others. In this case, perhaps CAPS1 editing influences secretion from PC-12s and neurons
differently than INS-1 cells due to unique properties of those cells. It would be interesting to
expand these studies, identifying secretion phenotypes of other cell types and lines in response to
alterations to CAPS1 editing. Knowledge of how/if CAPS1 editing affects stimulated and nonstimulated secretion in a variety of cell types may provide insight into how RNA editing
dependent isoforms of CAPS1 interact with subcellular machinery to affect secretion. It is
possible editing-dependent phenotypes require a specific component unique to certain cell types
to differentially affect non-stimulated or stimulated secretion. Identifying the factors common to
cell types that have similar CAPS1-dependent secretion phenotypes could help identify the
components or factors involved.
Recoding of CAPS1 by RNA editing is known to alter protein-protein interactions. For
example, Syntaxin-1A preferentially binds to edited-Caps1 compared to non-edited Caps1.
While both closed and open forms of Syntaxin-1A bind to edited Caps1, the interaction between
edited Caps1 and the open form is stronger (Parsaud et al., 2013). Syntaxin-1A is abundant in
both PC-12 cells (Miyake et al., 2016) and neural cells (Vardar et al., 2016). However, Syntaxin1A is mainly found at the membrane and involved with the first phase of insulin release within
pancreatic beta cells, while Syntaxin-3 is associated with the second phase of insulin release
(Zhu et al., 2013). Since Syntaxin-1A preferentially binds to edited Caps1, it is possible this
relationship is responsible for secretion effects and for potential differences in CAPS1 editingdependent isoforms in different cell types. Perhaps, edited CAPS1 had no effects on calciummediated secretion in INS-1 cells due to the limited availability of Syntaxin-1A. In this case,
overexpressing Syntaxin-1A, or replacing Syntaxin-3 with Syntaxin-1A, while increasing levels
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of CAPS1 editing would have secretion effects similar to neurons or PC-12 cells. We might
expect these editing-dependent phenotypes to deplete in a Syntaxin-1A knockout model,
cementing the idea that editing-dependent CAPS1 affects are dependent upon the presence of
Syntaxin-1A. This experiment would also suggest editing of CAPS1 preferentially affects the
first phase of insulin release, and has a minimal to no effect on sustained, or second phase of
insulin release.
Much remains unknown about the mechanism or why modification of a single residue
within CAPS1 affects secretion. Future studies focusing on the residue re-coded by RNA editing
may be beneficial to understanding the mechanisms by which CAPS1 and RNA editing are
involved in secretion. To see the properties of glutamate and/or glycine that are responsible for
editing-dependent effects on secretion, endogenous CAPS1 could be replaced with variants that
encode different amino acids at the E/G site and then test how this modifies secretion. One could
also test the interaction of these variants with Syntaxin-1A or with the vesicle itself to help us
understand the biochemistry of the interaction. It is possible that glycine and amino acids with
similar charge and polarity have similar effects on secretion, similarly interact with Syntaxin-1A
and with the vesicle, and similarly affect vesicle organization. Perhaps these qualities contrast
the behavior of Caps1 isoforms containing amino acids charged similarly to glutamate. This
information would provide insight into the impact glutamate, and ultimately RNA editing, has on
Caps1 structure and its function in vesicle fusion.

Pursuit to Understand RNA Editing Within CAPS1 and Its Effect on Secretion
To summarize, the results in our study bring clear future directions for how we can
continue to uncover the mysteries of how RNA editing within CAPS1 affects LDCV fusion. The
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immediate next steps to continue this work include identifying and/or deploying alternate
strategies to alter the editing frequency of CAPS1 within the INS-1 cells. Stimulating secretion
with high potassium is also an important step. Along the way, it may be prudent to identify an
alternative secretagogue (e.g. insulin or Phogrin-YFP) and compare its secretion to that of NPYGFP. More involved future projects could focus on how the biochemistry of the E/G site is
involved in secretion, giving insights to how this one amino acid change can affect a highly
regulated cellular process through protein-protein interactions, association with the vesicle,
and/or organization of the vesicles themselves. Perhaps as the work moves forward, even more
questions will be compelled, and this work will pave the way to a deeper understanding how
LDCV fusion is regulated.
Information on how alterations to CAPS1 editing frequency or increasing levels of
CAPS1 isoforms are important when considering potential therapies or consequences of
biological conditions that might alter editing or CAPS1 levels. For example, CAPS family has
been shown to be involved in patients with intellectual disabilities. Dysregulation of CAPS1 and
CAPS2 causes phenotypes similar to autism while deletion of CAPS1 causes learning difficulties,
delayed social development, and language impairments (reviewed in de la Hoz et al., 2015).
Dysregulation of CAPS1 and 2 in mouse pancreatic beta cells leads to loss of glucose sensitivity,
a characteristic of diabetes (Speidel et al., 2008). Thus, it is clear that proper maintenance of
neurotransmission and glucose tolerance rely on Caps1. CAPS1 and its role in secretion are vital
in maintaining body homeostasis. Therefore, regulating CAPS1 is paramount to homeostasis and
health, and RNA editing is just one of many steps involved in that regulation.

65

REFERENCES

Aravanis, A. M., Pyle, J. L., and Tsien, R. W. (2003). Single synaptic vesicles fusing transiently
and successively without loss of identity. Nature 423, 643–647. doi:10.1038/nature01686
Arunachalam, L., Han, L., Tassew, N. G., He, Y., Wang, L., Xie, L., and Sugita, S. (2008).
Munc18-1 is critical for plasma membrane localization of syntaxin1 but not of SNAP-25 in
PC12 cells. Mol. Biol. Cell 19, 722–734. doi:10.1091/mbc.E07-07-0662
Band, A. M., and Kuismanen, E. (2005). Localization of plasma membrane t-SNAREs syntaxin
2 and 3 in intracellular compartments. BMC Cell Biol. 6, 26. doi:10.1186/1471-2121-6-26
Barg, S., Eliasson, L., Renström, E., and Rorsman, P. (2002). A subset of 50 secretory granules
in close contact with L-type Ca2+ channels accounts for first-phase insulin secretion in
mouse β-cells. Diabetes 51. doi:10.2337/diabetes.51.2007.s74
Bennett, M. K., Calakos, N., and Scheller, R. H. (1992). Syntaxin: A synaptic protein implicated
in docking of synaptic vesicles at presynaptic active zones. Science 257:5067, 255–259.
doi:10.1126/science.1321498
Betz, A., Okamoto, M., Benseler, F., and Brose, N. (1997). Direct interaction of the rat unc-13
homologue munc13-1 with the N terminus of syntaxin. J. Biol. Chem. 272:4, 2520–2526.
doi:10.1074/jbc.272.4.2520
Borisovska, M. (2018). Syntaxins on granules promote docking of granules via interactions with
munc18. Scientific Reports 8:1. doi:10.1038/s41598-017-18597-z
Borisovska, M., Schwarz, Y. N., Dhara, M., Yarzagaray, A., Hugo, S., Narzi, D., and Bruns, D.
(2012). Membrane-proximal tryptophans of synaptobrevin II stabilize priming of secretory
vesicles. J. Neurosci. 32:45, 15983–15997. doi:10.1523/JNEUROSCI.6282-11.2012
Braun, M., Ramracheya, R., Johnson, P. R., Rorsman, P. 2009. NYAS 1152, 187-193.
https://doi.org.10.1111/j.1749-6632.2008.03992.x.
Caromile, L. A., Oganesian, A., Coats, S. A., Seifer, R. A., and Bowen-Pope, D. F. (2010). The
neurosecretory vesicle protein phogrin functions as a phosphatidylinositol phosphatase to
regulate insulin secretion. J. Biol. Chem. 285:14, 10487–10496.
doi:10.1074/jbc.M109.066563
Ceccarelli, B., Hurlbut, W. P., and Mauro, A. (1973). Turnover of transmitter and synaptic
vesicles at the prog neuromuscular junction. J. Cell Biol. 57:2, 499–524.
doi:10.1083/jcb.57.2.499
Chalk, A. M., Taylor, S., Heraud-Farlow, J. E., and Walkley, C. R. (2019). The majority of A-toI RNA editing is not required for mammalian homeostasis. Genome Biol. 20:1, 1–14.
doi:10.1186/s13059-019-1873-2
66

Chapman, E. R. (2008). How Does Synaptotagmin Trigger Neurotransmitter Release? Annual
Review of Biochemistry 77:1, 615–641. doi:10.1146/annurev.biochem.77.062005.101135
Chen, C., Cohrs, C. M., Stertmann, J., Bozsak, R., and Speier, S. (2017). Human beta cell mass
and function in diabetes: Recent advances in knowledge and technologies to understand
disease pathogenesis. Molecular Metabolism 6, 943–957.
doi:10.1016/j.molmet.2017.06.019
Chen, C. X., Cho, D. S., Wang, Q., Lai, F., Carter, K. C., and Nishikura, K. (2000). A third
member of the RNA-specific adenosine deaminase gene family, ADAR3, contains both
single- and double-stranded RNA binding domains. RNA 6:5, 755–767. Retrieved from
http://www.ncbi.nlm.nih.gov/pubmed/10836796
Cho, D.-S. C., Yang, W., Lee, J. T., Shiekhattar, R., Murray, J. M., and Nishikura, K. (2003).
Requirement of Dimerization for RNA Editing Activity of Adenosine Deaminases Acting
on RNA. J. Biol. Chem. 278:19, 17093–17102. doi:10.1074/jbc.M213127200
Chung, C., and Raingo, J. (2013). Vesicle dynamics: How synaptic proteins regulate different
modes of neurotransmission. Journal of Neurochemistry 126:2, 146–154.
doi:10.1111/jnc.12245
Cook, D. L., and Hales, N. (1984). Intracellular ATP directly blocks K+ channels in pancreatic
B-cells. Nature 311:5983, 271–273. doi:10.1038/311271a0
Cox, D. B. T., Gootenberg, J. S., Abudayyeh, O. O., Franklin, B., Kellner, M. J., Joung, J., and
Zhang, F. (2017). RNA editing with CRISPR-Cas13. Science 358:6366, 1019-1027.
https://doi.org.10.1126/science.aaq0180.
Daily, N. J., Boswell, K. L., James, D. J., and Martin, T. F. J. (2010). Novel interactions of
CAPS (Ca2+-dependent activator protein for secretion) with the three neuronal SNARE
proteins required for vesicle fusion. J. Biol. Chem. 285:46, 35320–35329.
doi:10.1074/jbc.M110.145169
de la Hoz, A. B., Maortua, H., García-Rives, A., Martínez-González, M. J., Ezquerra, M., and
Tejada, M.-I. (2015). 3p14 De Novo Interstitial Microdeletion in a Patient with Intellectual
Disability and Autistic Features with Language Impairment: A Comparison with Similar
Cases. Case Reports in Genetics 1–7. doi:10.1155/2015/876348
Deng, P., Khan, A., Jacobson, D., Sambrani, N., Mcgurk, L., Li, X., and Keegan, L. P. (2020).
Immune functions in Drosophila, 1–13.
Dulubova, I., Sugita, S., Hill, S., Hosaka, M., Fernandez, I., Südhof, T. C., and Rizo, J. (1999). A
conformational switch in syntaxin during exocytosis: Role of munc18. EMBO 18:16, 4372–
4382. doi:10.1093/emboj/18.16.4372
El Meskini, R., Jin, L., Marx, R., Bruzzaniti, A., Lee, J., Emeson, R. B., and Mains, R. E. (2001).
A signal sequence is sufficient for green fluorescent protein to be routed to regulated
secretory granules. Endocrinology 142:2, 864–873. doi:10.1210/endo.142.2.7929
67

Gallo, A., and Locatelli, F. (2012). ADARs: Allies or enemies? The importance of A-to-I RNA
editing in human disease: From cancer to HIV-1. Biological Reviews 87:1, 95–110.
doi:10.1111/j.1469-185X.2011.00186.x
Gerber, A. P., and Keller, W. (1999). An adenosine deaminase that generates inosine at the
wobble position of tRNAs. Science 286:5442, 1146–1149. Retrieved from
http://www.ncbi.nlm.nih.gov/pubmed/10550050
Giner, D., Lopez., I., Willanueva, J., Torres, V., Viniegra, S., Gutierrez, L. M. (2011). The Factin cortical network is a major factor influencing the organization of the secretory
machinery in chromaffin cells. J. Cell Sci. 124. https://doi.org.10.1242/jcs.078600
Goda, Y. (1997). Commentary SNAREs and regulated vesicle exocytosis. PNAS, 94:3, 769-772.
doi:10.1073/pnas.94.3.769
Green, M. R., and Sambrook, J. (2019). Screening Colonies by Polymerase Chain Reaction
(PCR). Cold Spring Harbor Protocols, 2019:6. doi:10.1101/pdb.prot095224
Greengard, P., Valtorta, F., Czernik, A. J., and Benfenati, F. (1993). Synaptic vesicle
phosphoproteins and regulation of synaptic function. Science 259:5096, 780–785.
doi:10.1126/science.8430330
Grishanin, R. N., Klenchin, V. A., Loyet, K. M., Kowalchyk, J. A., Ann, K., and Martin, T. F. J.
(2002). Membrane association domains in Ca2+-dependent activator protein for secretion
mediate plasma membrane and dense-core vesicle binding required for Ca2+-dependent
exocytosis. J. Biol. Chem. 277:24, 22025–22034. doi:10.1074/jbc.M201614200
Gulyás-Kovács, A., De Wit, H., Milosevic, I., Kochubey, O., Toonen, R., Klingauf, J., and
Sørensen, J. B. (2007). Munc18-1: Sequential interactions with the fusion machinery
stimulate vesicle docking and priming. J. Neurosci. 27:32, 8676–8686.
doi:10.1523/JNEUROSCI.0658-07.2007
Han, J., Pluhackova, K., Bruns, D., and Böckmann, R. A. (2016). Synaptobrevin transmembrane
domain determines the structure and dynamics of the SNARE motif and the linker region.
Biochim. Biophys. Acta Biomembr. 1858:4, 855–865. doi:10.1016/j.bbamem.2016.01.030
Henquin, J., Ishiyama, N., Nenquin. M., Ravier, M. A., Jonas, J. C. (2002). Signals and Pools
Imderlying Biphasic Insulin Secretion. Diabetes 51:1.
ttps://doi.org/10.2337/diabetes.51.2007.S60
Herbert, A., Wagner, S., and Nickerson, J. A. (2002). Induction of Protein Translation by
ADAR1 within living cell nuclei is not dependent on RNA editing. In J. Mol. Cell 10:5.
https://doi.org.10.1016/s1097-2765(02)00737-2.
Hood, J. L., Morabito, M. V., Martinez, C. R., Gilbert, J. A., Ferrick, E. A., Ayers, G. D., and
Emeson, R. B. (2014). Reovirus-mediated induction of ADAR1 (p150) minimally alters
RNA editing patterns in discrete brain regions. Mol. Cell. Neurosci. 61, 97–109.
doi:10.1016/j.mcn.2014.06.001
68

Jacobs, M. M., Fogg, R. L., Emeson, R. B., and Stanwood, G. D. (2009). ADAR1 and ADAR2
expression and editing activity during forebrain development. Dev. Neuro. 31:3, 223–237.
doi:10.1159/000210185
Jahn, R., and Südhof, T. C. (1999). Membrane fusion and exocytosis. Annual Reviews
Biochemistry, 68, 863-911. https:/doi.org/10.1146/annurev.biochemi.68.1.863
James, D. J., and Martin, T. F. J. (2013). CAPS and Munc13: CATCHRs that SNARE vesicles.
Frontiers in Endocrinology 4:187. doi:10.3389/fendo.2013.00187
Kavalali, E. T. (2015, December 19). The mechanisms and functions of spontaneous
neurotransmitter release. Nat. Neuro. 16, 5–16. doi:10.1038/nrn3875
Kelly, R. B. (1993). Storage and release of neurotransmitters. Cell 72, 43–53.
doi:10.1016/s0092-8674(05)80027-3
Khodthong, C., Kabachinski, G., James, D. J., and Martin, T. F. J. (2011). Munc13 Homology
Domain-1 in CAPS/UNC31 Mediates SNARE Binding Required for Priming Vesicle
Exocytosis. Cell Metabolism 14:2, 254–263. doi:10.1016/j.cmet.2011.07.002
Kim, U., Wang, Y., Sanford, T., Zeng, Y., and Nishikura, K. (1994). Molecular cloning of cDNA
for double-stranded RNA adenosine deaminase, a candidate enzyme for nuclear RNA
editing. NAS 91:24, 11457–11461. Retrieved from
http://www.ncbi.nlm.nih.gov/pubmed/7972084
Klenchin, V. A., and Martin, T. F. J. (2000). Priming in exocytosis: Attaining fusion-competence
after vesicle docking. Biochimie 82:5, 399–407. doi:10.1016/S0300-9084(00)00208-X
Koeck, P., Bastiaens, H., Benhalima, K., Cloetens, H., Feyen, L., Sunaert, P., and Nobels, F.
(2015). Richtlijn Diabetes Mellitus Type 2. Retrieved from
https://domusmedica.be/sites/default/files/Richtlijn Diabetes_0.pdf
Komatsu, M., Takei, M., Ishii, H., and Sato, Y. (2013). Glucose-stimulated insulin secretion:
oflA newer perspective. J. Diabetes Investigation 4:6, 511–516. doi:10.1111/jdi.12094
Krebs, J. E., Lewis, B., Kilpatrick, S. T., and Goldstein E. S. (2018). Lewin's genes XII.
Burlington, MA: Jones and Bartlett Learning.
Kunkel, G. R., Maser, R. L., Calvet, J. P., and Pederson, T. (1986). U6 small nuclear RNA is
transcribed by RNA polymerase III. NAS 83:22, 8575–8579. doi:10.1073/pnas.83.22.8575
Lehmann, K. A., and Bass, B. L. (1999). The importance of internal loops within RNA substrates
of ADAR1. J. Mol. Biol. 291:1, 1–13. doi:10.1006/jmbi.1999.2914
Li, Jin Billy, Levanon, E. Y., Yoon, J.-K., Aach, J., Xie, B., Leproust, E., and Church, G. M.
(2009). Genome-wide identification of human RNA editing sites by parallel DNA capturing
and sequencing. Science 324:5931, 1210–1213. doi:10.1126/science.1170995

69

Li, W., Ma, C., Guan, R., Xu, Y., Tomchick, D. R., and Rizo, J. (2011). The Crystal Structure of
a Munc13 C-terminal Module Exhibits a Remarkable Similarity to Vesicle Tethering
Factors. Structure 19:10, 1443–1455. doi:10.1016/j.str.2011.07.012
Liscovitch-Brauer, N., Alon, S., Porath, H. T., Elstein, B., Unger, R., Ziv, T., and Eisenberg, E.
(2017). Trade-off between Transcriptome Plasticity and Genome Evolution in Cephalopods.
Cell 169:2, 191-202. doi:10.1016/j.cell.2017.03.025
Liu, Y., Schirra, C., Edelmann, L., Matti, U., Rhee, J. S., Hof, D., and Rettig, J. (2010). Two
distinct secretory vesicle-priming steps in adrenal chromaffin cells. J. Cell Biol. 190:6,
1067–1077. doi:10.1083/jcb.201001164
Longo, P. A., Kavran, J. M., Kim, M.-S., and Leahy, D. J. (2013). Transient mammalian cell
transfection with polyethylenimine (PEI). Methods in Enzymology 529, 227–240.
doi:10.1016/B978-0-12-418687-3.00018-5
Lou, X., and Shin, Y. K. (2016). SNARE zippering. Bioscience Reports 36:3, 1–7.
doi:10.1042/BSR20160004
Low, S. H., Chapin, S. J., Weimbs, T., Koimuives, L. G., Bennett, M. K., and Mostov, K. E.
(2007). Differential Localization of Syntaxin Isoforms in Polarized Madin-Darby Canine
Kidney Cells. In Mol. Biol. Cell 7:12, 2007-2018. doi: 10.1091/mbc.7.12.2007
Lupas, A. N., and Gruber, M. (2005). The structure of α-helical coiled coils. Advances in Protein
Chemistry 70, 37–38. doi:10.1016/S0065-3233(05)70003-6
Ma, L., Bindokas, V. P., Kuznetsov, A., Rhodes, C., Hays, L., Michael Edwardson, J., and
Philipson, L. H. (2004). Direct imaging shows that insulin granule exocytosis occurs by
complete vesicle fusion. PNAS 101:25, 9266-9271. doi:10.1073/pnas.0403201101
Maas, S, Melcher, T., and Seeburg, P. H. (1997). Mammalian RNA-dependent deaminases and
edited mRNAs. Current Opinion in Cell Biology 9:3, 343–349. doi:10.1016/S09550674(97)80006-3.
Maas, Stefan, and Gommans, W. M. (2009). Identification of a selective nuclear import signal in
adenosine deaminases acting on RNA. Nucleic Acids Research 37:17, 5822–5829.
doi:10.1093/nar/gkp599
Martin, T. F. J. (2014). PI(4,5)P 2-binding effector proteins for vesicle exocytosis. Biochim.
Biohys. Acta Biomembr. 1851:6, 785-93. doi:10.1016/j.bbalip.2014.09.017
Mishima, T., Fujiwara, T., Sanada, M., Kofuji, T., Kanai-Azuma, M., and Akagawa, K. (2014).
Syntaxin 1B, but not syntaxin 1A, is necessary for the regulation of synaptic vesicle
exocytosis and of the readily releasable pool at central synapses. PLoS ONE 9:2.
doi:10.1371/journal.pone.0090004
Miyake, K., Ohta, T., Nakayama, H., Doe, N., Terao, Y., Oiki, E., and Kawahara, Y. (2016).
CAPS1 RNA Editing Promotes Dense Core Vesicle Exocytosis. Cell Reports 17:8, 2004–
70

2014. doi:10.1016/j.celrep.2016.10.073
Nagy, G., Matti, U., Nehring, R. B., Binz, T., Rettig, J., Neher, E., and Sørensen, J. B. (2002).
Protein kinase C-dependent phosphorylation of synaptosome-associated protein of 25 kDa
at Ser187 potentiates vesicle recruitment. J. Neurosci. 22:21, 9278–9286.
doi:10.1523/jneurosci.22-21-09278.2002
Nakata, T. and N. Hirokawa. (1992). Organization of cortical cytoskeleton of cultured
chromaffin cells and involvement in secretion as revealed by quick-freeze, deep-etching,
and double-label immunoelectron microscopy. J. Neurosci. 12:6.
https://doi.org.10.1523/JNEUROSCIE. 12-06-02186
Nishikura, K. (2010). Functions and Regulation of RNA Editing by ADAR Deaminases. Annual
Review of Biochemistry 79:1, 321–349. doi:10.1146/annurev-biochem-060208-105251
Nishizakis, T., Walent, J. H., Kowalchyk, J. A., and Martins, T. F. J. (1992). A Key Role for a
145-kDa Cytosolic Protein in the Stimulation of Ca2+-dependent Secretion by Protein
Kinase C. The J. Biol. Chem.267:33.
Nofal, S., Becherer, U., Hof, D., Matti, U., Rettig, J. 2007. J. Neurosci. 27:6, 1386-1395.
doi:10.1523/JNEUROSCI.4714-06.2007.
Nojiri, M., Loyet, K. M., Klenchin, V. A., Kabachinski, G., Martin, T. F. J., and Martin, T. F. J.
(2009). CAPS activity in priming vesicle exocytosis requires CK2 phosphorylation. J. Biol.
Chem. 284:28, 18707–18714. doi:10.1074/jbc.M109.017483
Ohara-Imaizumi, M., Fujiwara, T., Nakamichi, Y., Okamura, T., Akimoto, Y., Kawai, J., and
Nagamatsu, S. (2007). Imaging analysis reveals mechanistic differences between first- and
second-phase insulin exocytosis. J. Cell Biol. 177:4, 695–705. doi:10.1083/jcb.200608132
Park, S., Bin, N. R., Rajah, M. M., Kim, B., Chou, T. C., Kang, S. Y. A., and Sugita, S. (2016).
Conformational states of syntaxin-1 govern the necessity of N-peptide binding in exocytosis
of PC12 cells and Caenorhabditis elegans. Mol. Biol. Cell 27:4, 669–685.
doi:10.1091/mbc.E15-09-0638
Park, Y. S., Hur, E. M., Choi, B. H., Kwak, E., Jun, D. J., Park, S. J., and Kim, K. T. (2006a).
Involvement of protein kinase C-ε in activity-dependent potentiation of large dense-core
vesicle exocytosis in chromaffin cells. J. Neurosci. 26:35, 8999–9005.
doi:10.1523/JNEUROSCI.2828-06.2006
Park, Y. S., Hur, E. M., Choi, B. H., Kwak, E., Jun, D. J., Park, S. J., and Kim, K. T. (2006b).
Involvement of protein kinase C-ε in activity-dependent potentiation of large dense-core
vesicle exocytosis in chromaffin cells. J. Neurosci. 26:35, 8999–9005.
doi:10.1523/JNEUROSCI.2828-06.2006
Parsaud, L., Li, L., Jung, C. H., Park, S., Saw, N. M. N., Park, S., and Sugita, S. (2013).
Calcium-dependent activator protein for secretion 1 (CAPS1) binds to syntaxin-1 in a
distinct mode from Munc13-1. J. Biol. Chem. 288:32, 23050–23063.
71

doi:10.1074/jbc.M113.494088
Peng, Z., Cheng, Y., Tan, B. C. M., Kang, L., Tian, Z., Zhu, Y., and Wang, J. (2012).
Comprehensive analysis of RNA-Seq data reveals extensive RNA editing in a human
transcriptome. Nature Biotechnology 30:3, 253–260. doi:10.1038/nbt.2122
Petrie, M., Esquibel, J., Greg Kabachinski, X., Maciuba, S., Takahashi, H., Michael Edwardson,
X. J., and Thomas J Martin, X. F. (2016). The Vesicle Priming Factor CAPS Functions as a
Homodimer via C2 Domain Interactions to Promote Regulated Vesicle Exocytosis. J. Biol.
Chem. 291:40. doi:10.1074/jbc.M116.728097
Pinto, Y., Cohen, H. Y., and Levanon, E. Y. (2014). Mammalian conserved ADAR targets
comprise only a small fragment of the human editosome. Genome Biology 15:1, 31–33.
doi:10.1186/gb-2014-15-1-r5
Poirier, M. A., Xiao, W., Macosko, J. C., Chan, C., Shin, Y. K., and Bennett, M. K. (1998). The
synaptic SNARE complex is a parallel four-stranded helical bundle. Nature Structural
Biology 5:9, 765–769. doi:10.1038/1799
Prasanth, K. V, Prasanth, S. G., Xuan, Z., Hearn, S., Freier, S. M., Bennett, C. F., and Spector,
D. L. (2005). Regulating gene expression through RNA nuclear retention. Cell 123:2, 249–
263. doi:10.1016/j.cell.2005.08.033
Qu, L., Yi, Z., Zhu, S., Wang, C., Cao, Z., Zhou, Z., and Wei, W. (2019). Programmable RNA
editing by recruiting endogenous ADAR using engineered RNAs. Nature Biotechnology,
37:9, 1059–1069. doi:10.1038/s41587-019-0178-z
Ramakrishnan, N. A., Drescher, M. J., and Drescher, D. G. (2012). The SNARE complex in
neuronal and sensory cells. Mol. Cell. Neurosci. 50:1. doi:10.1016/j.mcn.2012.03.009
Risselada, H. J., and Mayer, A. (2020). SNAREs, tethers and SM proteins: How to overcome the
final barriers to membrane fusion? Biochemi. J. 477:1, 243–258. doi:10.1042/BCJ20190050
Rizzoli, S. O., and Betz, W. J. (2005). Synaptic vesicle pools. Nat. Neurosci. 6:1, 57–69.
doi:10.1038/nrn1583
Rong, L., and Perelson, A. S. (2010). Treatment of hepatitis c virus infection with interferon and
small molecule direct antivirals: Viral kinetics and modeling. Critical Reviews in
Immunology 30, 131–148. doi:10.1615/critrevimmunol.v30.i2.30
Rorsman, P., and Renstrom, E. (2003). Insulin granule dynamics in pancreatic beta cells.
Diabetologia 46:8, 1029–1045. doi:10.1007/s00125-003-1153-1
Rorsman, Patrik, and Huising, M. O. (2018). The somatostatin-secreting pancreatic δ-cell in
health and disease. Nature Reviews Endocrinology 14. doi:1 0.1038/s41574-018-0020-6
Rosenthal, J. J. C. (2015). The emerging role of RNA editing in plasticity. Journal of
Experimental Biology 218:12, 1812–1821. doi:10.1242/jeb.119065

72

Rueter, S. M., and Emeson, R. B. (1998). Adenosine-to-Inosine Conversion in mRNA.
Modification and Editing of RNA, 343–361. doi:10.1128/9781555818296.ch19
Rutter, G. A., and Hill, E. V. (2006). Insulin Vesicle Release: Walk, Kiss, Pause … Then Run.
Phys. 21:3, 189–196. doi:10.1152/physiol.00002.2006
Sadakata, T., Kakegawa, W., Shinoda, Y., Hosono, M., Katoh-Semba, R., Sekine, Y., and
Furuichi, T. (2013). CAPS1 deficiency perturbs dense-core vesicle trafficking and golgi
structure and reduces presynaptic release probability in the mouse brain. J. Neurosci. 33:44,
17326–17334. doi:10.1523/JNEUROSCI.2777-13.2013
Satin, L. S. (2000). Localized calcium influx in pancreatic β-cells: Its significance for Ca2+dependent insulin secretion from the islets of Langerhans. Endocrine 13, 251–262.
doi:10.1385/ENDO:13:3:251
Shen, C., Rathore, S. S., Yu, H., Gulbranson, D. R., Hua, R., Zhang, C., and Shen, J. (2015). The
trans-SNARE-regulating function of Munc18-1 is essential to synaptic exocytosis. Nature
Communications 6, 1–21. doi:10.1038/ncomms9852
Speidel, D., Salehi, A., Obermueller, S., Lundquist, I., Brose, N., Renström, E., and Rorsman, P.
(2008). CAPS1 and CAPS2 Regulate Stability and Recruitment of Insulin Granules in
Mouse Pancreatic β Cells. Cell Metabolism 7:1, 57–67. doi:10.1016/j.cmet.2007.11.009
Stevens, D. R., Schirra, C., Becherer, U., and Rettig, J. (2011). Vesicle pools: Lessons from
adrenal chromaffin cells. Frontiers in Synaptic Neuroscience 3:2.
doi:10.3389/fnsyn.2011.00002
Taguchi, N. (1995). Mechanism of glucose-induced biphasic insulin release: physiological role
of adenosine triphosphate-sensitive K+ channel-independent glucose action. Endocrinology
136:9, 3942–3948. doi:10.1210/en.136.9.3942
Tang, J., Maximov, A., Shin, O. H., Dai, H., Rizo, J., and Südhof, T. C. (2006). A
Complexin/Synaptotagmin 1 Switch Controls Fast Synaptic Vesicle Exocytosis. Cell 126:6,
1175–1187. doi:10.1016/j.cell.2006.08.030
Teng, B., Verp, M., Salomon, J., and Davidson, N. O. (1990). Apolipoprotein B messenger RNA
editing is developmentally regulated and widely expressed in human tissues. J. Biol. Chem.
265:33, 20616–20620.
Ulbricht, R. J., Sun, S. J., Delbove, C. E., Kitko, K. E., Rehman, S. C., Wang, M. Y. and
Emeson, R. B. (2017). RNA editing of CAPS1 regulates synaptic vesicle organization,
release and retrieval. bioRxiv. doi:10.1101/178202
van Keimpema, L., Kooistra, R., Toonen, R. F., and Verhage, M. (2017). CAPS-1 requires its
C2, PH, MHD1 and DCV domains for dense core vesicle exocytosis in mammalian CNS
neurons. Scientific Reports 7:1, 10817. doi:10.1038/s41598-017-10936-4
Vardar, G., Chang, S., Arancillo, M., Wu, Y. J., Trimbuch, T., and Rosenmund, C. (2016).
73

Distinct functions of syntaxin-1 in neuronal maintenance, synaptic vesicle docking, and
fusion in mouse neurons. J. Neurosci. 36:30, 7911–7924. doi:10.1523/JNEUROSCI.131416.2016
Vardjan, N., Stenovec, M., Jorgačevski, J., Kreft, M., and Zorec, R. (2007). Elementary
properties of spontaneous fusion of peptidergic vesicles: Fusion pore gating. J. Phys. 585:3,
655–661. doi:10.1113/jphysiol.2007.136135
Vaughan, P. F., Walker, J. H., and Peers, C. (1998). The regulation of neurotransmitter secretion
by protein kinase C. Molecular Neurobiology 18:2, 125–155. doi:10.1007/bf02914269
Verhage, M., Maia, A. S., Plomp, J. J., Brussaard, A. B., Heeroma, J. H., Vermeer, H., and
Südhof, T. C. (2000). Synaptic assembly of the brain in the absence of neurotransmitter
secretion. Science 287:5454, 864–869. doi:10.1126/science.287.5454.864
Verhage, M., and Sørensen, J. B. (2008). Vesicle Docking in Regulated Exocytosis. Traffic 9:9,
1414–1424. doi:10.1111/j.1600-0854.2008.00759.x
Vitale, M. L., Seward, E. P., and Trifaro, J. M. (1995). Chromaffin Cell Cortical Actin Network
Dynamics Control the Size of the Release-Ready Vesicle Pool and the Initial Rate of
Exocytosis. Neuron 14, 353-363. doi:10.1016/0896-6273(95)90291-0.
Voets, T., Toonen, R. F., Brian, E. C., De Wit, H., Moser, T., Rettig, J., and Verhage, M. (2001).
Munc18-1 promotes large dense-core vesicle docking. Neuron 31:4, 581–592.
doi:10.1016/S0896-6273(01)00391-9
Waeber, G., Thompson, N., Waeber, B., Brunner, H. R., Nicod, P., and Grouzmann, E. (1993).
Neuropeptide Y expression and regulation in a differentiated rat insulin-secreting cell line.
Endocrinology 133:3, 1061–1067. doi:10.1210/endo.133.3.8396008
Wang, S., Choi, U. B., Gong, J., Yang, X., Li, Y., Wang, A. L., and Ma, C. (2017).
Conformational change of syntaxin linker region induced by Munc13s initiates SNARE
complex formation in synaptic exocytosis. EMBO J. 36:6, 816–829.
doi:10.15252/embj.201695775
Weng, S., Janssen, H. L. A., Zhang, N., Tang, W., Bai, E., Yang, B., and Dong, L. (2019).
CAPS1 Suppresses Tumorigenesis in Cholangiocarcinoma. Digestive Diseases and
Sciences 65:4. doi:10.1007/s10620-019-05843-9
Williams, D., Vicôgne, J., Zaitseva, I., McLaughlin, S., and Pessin, J. E. (2009). Evidence that
electrostatic interactions between vesicle-associated membrane protein 2 and acidic
phospholipids may modulate the fusion of transport vesicles with the plasma membrane.
Mol. Biol. Cell 20:23, 4910–4919. doi:10.1091/mbc
Wollheim, C. B., and Sharp, G. W. (1981). Regulation of insulin release by calcium.
Physiological Reviews 61, 914–973. doi:10.1152/physrev.1981.61.4.914
Xu, G., and Zhang, J. (2014). Human coding RNA editing is generally nonadaptive. NAS 111:10,
74

3769–3774. doi:10.1073/pnas.1321745111
Xu, Jun, Pang, Z. P., Shin, O. H., and Südhof, T. C. (2009). Synaptotagmin-1 functions as a
Ca2+ sensor for spontaneous release. Nat. Neurosci. 12:6, 759–766. doi:10.1038/nn.2320
Xu, Junjie, Camacho, M., Xu, Y., Esser, V., Liu, X., Trimbuch, T., and Rizo, J. (2017).
Mechanistic insights into neurotransmitter release and presynaptic plasticity from the crystal
structure of Munc13-1 C1C2BMUN. ELife 6. doi:10.7554/eLife.22567
Xue, R., Tang, W., Dong, P., Weng, S., Ma, L., Chen, S., and Dong, L. (2016). CAPS1
negatively regulates hepatocellular carcinoma development through alteration of
exocytosis-associated tumor microenvironment. International J. Mol. Sci. 17:10.
doi:10.3390/ijms17101626
Yang, J. H., Luo, X., Nie, Y., Su, Y., Zhao, Q., Kabir, K., and Rabinovici, R. (2003).
Widespread inosine-containing mRNA in lymphocytes regulated by ADAR1 in response to
inflammation. Immunology 109:1, 15–23. doi:10.1046/j.1365-2567.2003.01598.x
Yang, L., Zhao, L., Gan, Z., He, Z., Xu, J., Gao, X., and Liu, Y. (2010). Deficiency in RNA
editing enzyme ADAR2 impairs regulated exocytosis. FASEB Journal 24:10, 3720–3732.
doi:10.1096/fj.09-152363
Zhu, D., Koo, E., Kwan, E., Kang, Y., Park, S., Xie, H., and Gaisano, H. Y. (2013). Syntaxin-3
regulates newcomer insulin granule exocytosis and compound fusion in pancreatic beta
cells. Diabetologia 56:2, 359–369. doi:10.1007/s00125-012-2757-0

75

